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The continual reassessment method (CRM) is a widely used model-based design
in Phase I dose-finding studies. This dissertation examines two extensions of CRM:
one is a two-stage method and the other is a method that accounts for patient het-
erogeneity. Originally proposed in the Bayesian framework, CRM starts by testing
the first patient at the prior guess of the maximum tolerated dose (MTD). However,
there are safety concerns with this approach as practitioners often prefer to start
from the lowest dose level and are reluctant to escalate to higher dose levels without
testing the lower ones with a sufficient number of patients. This calls for a two-stage
design, where the model-based phase is preceded by a pre-specified dose escalation
phase, and the phase transitions when any dose-limiting toxicity (DLT) occurs. In the
first part of this dissertation, I propose a theoretical framework to build a two-stage
CRM based on the coherence principle and prove the unique existence of the most
conservative and coherent initial design. An accompanying calibration algorithm is
formulated to facilitate design implementation. We demonstrate that by using real
trial examples, the algorithm yields designs with competitive performance compared
to the conventional design which uses a much more labor intensive trial-and-error
approach. Furthermore, we show that this algorithm can be applied in a timely and
reproducible manner.
In addition to the two-stage method, we also take into account of patient’s het-
erogeneity in drug metabolism rate that can result in different susceptibility to drug
toxicity. This led to a risk-adjusting design for identifying patient-specific MTDs.
The existing dose-finding designs which incorporate patient heterogeneity deal either
with only categorical risk factor or with continuous risk factor using models based
on strong parametric assumptions. We propose a method that uses a flexible semi-
parametric model to identify patient-specific MTDs, adjusting for either categorical
or continuous risk factor. Initially, our method assigns dose to patients using the
aforementioned two-stage CRM ignoring any patient heterogeneity, and tests the risk
effect as trial proceeds. It then transitions to a risk-adjusting stage only if sufficient
risk effect on toxicity outcome is observed. The performance of this multi-stage design
is evaluated under various scenarios, using dosing accuracy measures calculated based
on the final model estimate at the end of a trial and on the intra-trial dose allocation.
The results are compared to the conventional two-stage CRM without considering
patient heterogeneity. Simulation results demonstrate a substantial improvement in
dosing accuracy in scenarios where there are true risk effects on toxicity probability;
and in situations where risk factors do not have an effect, the performance of the
proposed method is also comparable to that of the conventional design.
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Chapter 1
Introduction
1.1 Phase I dose-finding study
Clinical trials are controlled experiments conducted on human beings to evaluate
the safety and effectiveness of new therapeutic regimen. They usually proceed through
several stages: Phase I, II and III, each with a different purpose. Following pre-clinical
and animal studies, Phase I trial is the first-in-human experiment, and it primarily
focuses on the safety of the drug. Within the trial, a discrete number of doses of
the experimental compound is studied, and one is identified as the most appropriate
dose under the pre-specified toxicity constraint. This is the dose with a toxicity
probability closest to the pre-specified target probability. It is also known as the
maximum tolerated dose (MTD). The rationale behind this approach is that toxicities
may serve as surrogate for tumor shrinkage in a patient undergoing cytotoxic cancer
treatment [7]. Such Phase I dose-finding studies usually use sequential designs.
There are two classes of sequential designs: rule-based and model-based. Origi-
nally used in oncology clinical trials, rule-based designs, such as “3+3”, were widely
adopted in Phase I trials. These designs follow a pre-specified rule to assign dose to
patients sequentially enrolled into the trial. Although simple enough, these designs
are rigid and do not have the flexibility to respond to unexpected addition of pa-
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tients or dose assignments. The design’s operating characteristics depends arbitrarily
on the underlying true dose-toxicity relationship and the MTD thus identified does
not correspond to any interpretable quantity upon repeated sampling. While “3+3”
method is considered safe, it has been criticized as over-conservative and tend to treat
patients excessively on low and inefficacious dose levels.
After O’Quigley [20] proposed the continual reassessment method (CRM), model-
based designs gained popularity. CRM approximates the true dose-toxicity relation-
ship through an increasing dose-toxicity function indexed by a single parameter. Dose
finding is formulated as a percentile estimation problem, in which, for a pre-specified
target toxicity probability, it aims to identify the dose level with an estimated dose
toxicity probability closest to this value; this is the dose at which the next patient will
be treated. Model based estimate converges fast to MTD, thus treats more patients
on the MTD than the “3+3” method. At the end of the trial, the data accumulated
throughout will be used to obtain the final estimate on the dose-toxicity curve and
the corresponding MTD.
1.2 Clinical Example: NeuSTART trial
The original CRM proposed by O’Quigley et al. in 1990 used the Bayesian frame-
work, and it usually treats the first patient enrolled into a trial on a prior guessed
MTD which is not necessarily the lowest dose level, and potentially skipping lower
dose levels without testing them. This can raise safety concerns as investigators often
prefer to start a trial from the lowest dose level and have a sufficient number of pa-
tients tested on each of these lower dose levels before escalating. A two-stage CRM
design can be used to satisfy this requirement. In such a design, the trial starts from
the lowest dose following a pre-specified dose assignment rule, and then switches to a
model-based design using the conventional CRM after the first toxicity occurs. The
following real trial example employed a two-stage design.
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NeuSTART was a multi-center Phase I dose-finding study. Its objective was to
determine the MTD of lovastatin for short-term acute stroke therapy [10]. The target
dose toxicity probability was 10%, and there were 5 dose levels. This study enrolled
33 patients with acute ischemic stroke in the trial. Lovastatin was administered in
increasing doses from 1 to 10 mg/kg daily for 3 days beginning within 24 hours after
symptom onset (Table 1.1). The primary safety event was occurrence of myotoxicity
or hepatotoxicity, defined by clinical and laboratory criteria, within a one month
period after treatment.
The original trial design used a two-stage CRM. Before any dose limiting toxicities
(DLT) occurred, the dose assignment followed a pre-specified dose escalation rule [10]:
the first and the second group of 3 patients would be assigned on dose level 1 (1 mg/kg)
and 2 (3 mg/kg), respectively, followed by 6 and 9 patients assigned on dose level
3 (6 mg/kg) and 4 (8 mg/kg), respectively. Twelve patients would be treated on
the highest dose level 5 (10 mg/kg). The second stage is activated when a primary
safety event is observed, at which time, the Bayesian CRM would be used to guide
the subsequent dose escalation process. The design parameters used in both stages
were determined using a trial-and-error approach described in Chapter 7 of Cheung
2011 [7].
1.3 Clinical Example: An oncology trial
The objective of this Phase I oncology trial was to determine an acceptable dose
among the five dose levels for a combination therapy of Gemcitabine, Cabazitaxel and
Cisplatin, to treat patients with non-muscle invasive bladder cancer via intravesical
administration. Gemcitabine and Cabazitaxel were the standard components and
Cisplatin was added as a third and experimental component. The dose of Gemcitabine
was fixed at 2g in all five dose levels, and the doses of Cabazitaxel and Cisplatin are
listed in Table 1.2. Cisplatin was only added on dose levels 3, 4, and 5. The toxicity
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Table 1.1: Dose levels in NeuSTART trial.






probabilities are expected to increase as dose level increases.
The MTD of this combination therapy is defined as the dose level associated
with a target probability of toxicity at 25%. DLT is defined as any grade 3 or 4
systemic toxicity or any grade 3 or 4 hematuria, dysuria, urinary retention, urinary
frequency/urgency, or bladder spasms using the NCI CTCAE version 4.0. Even
though the three-drug combination regimens are of ultimate interest, and MTD is
expected to be one of the three higher dose levels, physicians prefer to start the trial
by examining the toxicity tolerance of the standard therapy without Cisplatin, i.e.,
dose level 1 and 2. This requires conducting a two-stage design.
The above examples illustrate several scenarios where a two-stage design is used
in real world clinical studies. The major difference between a two-stage design and
the conventional one-stage Bayesian CRM is that the model-based phase is preceded
by a pre-specified escalation rule which dictates the initial dose escalation speed. The
fact that model based design is postponed after the first DLT is observed provides
an opportunity to use maximum likelihood estimation (MLE) rather than Bayesian
estimation. While the Bayesian method requires the use of a prior distribution on
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Table 1.2: Dose levels in the oncology trial.






model parameters that may be perceived as subjective and arbitrary, the likelihood
method does not have this limitation. However, two-stage designs open up new ques-
tions, e.g., how to choose a dose escalation sequence with an appropriate escalation
speed before model-based design is activated?
1.4 Clinical Example: Irinotecan individual dosing
trial
Conventional dose-finding studies usually identify a common MTD for all en-
rolled patients and infer that it is the MTD of the target study population. How-
ever, many risk factors such as treatment history and demographic characteristics are
known to influence the individual patient’s susceptibility to drug toxicity. A Phase I
dose-finding study that considers additional risk factors and identifies patient-specific
MTDs would lead to more accurate dose recommendations for subsequent Phase II
and III clinical trials. Such individualized dosing strategy will reduce both over-dosing
and under-dosing rates and optimize the drug’s therapeutic effect. In addition, us-
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ing a sequential design that considers individual differences in drug tolerability can
directly benefit the patients participating in the study, as the feedback from the infor-
mation accumulated during the trial can re-enforce the individualized dosing strategy
and yield more accurate dose allocations for subsequently enrolled patients.
Phase I dose-finding oncology studies often recruit end-stage cancer patients who
have failed standard therapies. The eligible patients could be fairly mixed in terms
of disease status, types of cancer, demographic and pharmacogenetic characteristics.
Analyses of multiple early phase clinical trials revealed that various patient character-
istics compete with dose as the predictors of the treatment toxicity rate [25]. National
Cancer Institute (NCI) accounts for the contribution of prior therapy by establishing
separate phase II doses for heavily pre-treated from minimally pre-treated patients.
Most clinical trials have already been practicing individualized dosing by administer-
ing doses adjusted for body surface area (BSA), a measure associated with weight
and height. It was also observed in numerous studies that older patients are more
likely to suffer from severe adverse events than younger patients.
Van der Bol et al. reported an individualized dosing trial for the drug irinotecan in
cancer patients [30]. The metabolism of irinotecan involves several enzymes and drug
transporters including members of the cyto-chrome P450 3A (CYP3A4) and uridine-
diphosphate glucuronosyltransferase 1A (UGT1A) families. Both enzymes play an
important role in clearing irinotecan, and hence, influence the level of its active form
in human body. CYP3A4, in particular, competes with the irinotecan activation
pathway and transforms irinotecan into inactive substrates. Meanwhile, UGT1A de-
activates the active form of irinotecan. Because the expression and function level
of these proteins could be affected by numerous environmental and genetic factors,
the pharmacokinetics of irinotecan and its active form could vary greatly among
patients. Such large inter-individual variability in the drug’s clearance ability may
result in over-treatment with unacceptable toxicities in some and under-treatment
with diminished therapeutic effects in others. The trial focused on the heterogeneity
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of irinotecan clearance and was designed to assess an individualized dosing algorithm
based on a few baseline variables associated with irinotecan clearance. Both UTG1A1
genotype and age (≤55 versus >55), as known confounders, were considered as strati-
fying factors, and patients were matched on the status of these two factors within each
treatment group and each participating institution. The dose given to each individ-
ual was derived from the predicted irinotecan clearance based on a linear regression
model of the historical data:
0.0325× midazolam clearance (ml/min) − 0.0396× γ − glutamyltransferase (units/L)
+27.180× height(m) − 31.926
where midazolam assay directly measures CYP3A4 activity, and γ-glutamyltransferase
is a biomarker for liver function. The study was a two-arm randomized study pow-
ered by 50% inter-individual variability reduction of irinotecan concentration area
under curve (AUC) in the individualized dosing arm compared to the control arm.
In the treatment arm, each patient’s predicted irinotecan clearance level is calculated
using the above equation. And then the respective dose is calculated by multiplying
the predicted clearance by 22.157 (µg × h/mL), which was the mean concentration
AUC of irinotecan observed previously and arbitrarily defined as the target measure
of the systemic exposure for this study. Those patients in the control arm were given
conventional doses based on BSA alone. Forty patients were randomized. Compared
with the conventional dosing arm, the individualized dosing arm decreased the inter-
individual variability in the AUC of irinotecan and its active form by 19% and 25%,
respectively, but the differences were not significant. The incidence of grades 3 to
4 neutropenia/leukopenia was about 4 folds lower in the individualized dosing arm
(p=0.013), and the incidence of grade 3 to 4 diarrhea was equal in both arms (10%).
The results show that the baseline CYP3A4 activity, as determined by midazolam
clearance, varied widely among enrolled patients: in a range of 203–1257 mL/min with
a mean of 698 mL/min (95% confidence interval 609-786 ml/min). The dose range
was much broader in the group using the individualized dosing algorithm (380-1060
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Table 1.3: Multi-variable analysis on irinotecan data set.
Any DLT
Variable log(OR) 95% CI p value
Irinotecan clearance -4.1 (-7.4,-0.8) 0.01
Dose 2.6 (-1.9,7.1) 0.3
vs 480-800 mg).
We pooled data from both arms and analyzed it using multi-variable logistic mod-
els. The binary toxicity endpoints include severe neutropenia, severe leukopenia, se-
vere diarrhea and combined endpoint of any severe toxicities (grade ≥ 3). Since the
irinotecan doses were determined by the predicted clearance level in half of the pa-
tients and by BSA in the other half, neither predicted clearance level and BSA were
considered as covariates in the analyses. The variables of interest included in the
models are log-transformed dose and log-transformed observed irinotecan clearance
(measured by midazolam assay). Irinotecan clearance is significantly associated with
the probability of severe leukopenia (p=0.02) and of any severe toxicities (p=0.01,
Table 1.3), adjusting for dose. No significant non-linear effect or interaction effect
was detected.
While this randomized study demonstrated interesting benefit of individualized
dosing, its dose calculation relies on historical data, which may not always align with
the data collected from the ongoing prospective study. It would be useful to conduct
such trial using sequential design, so that the heterogeneity information on drug
toxicity from early enrolled patients can be used to improve the dosing algorithm and
yield more accurate dose allocation on subsequently enrolled patients.
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As an outline of this dissertation, we will first review the basic components of
CRM and the existing dose-finding designs that incorporate patient heterogeneity in
Chapter 2. To address the two-stage design problem, in Chapter 3 we propose a
theoretical framework based on the coherence principle and characterize each design
component under this framework. In Chapter 4, we further derive a semi-automatic
calibration algorithm to facilitate the implementation of our method in practical
clinical settings and illustrate the application of the algorithm using NeuSTART trial
and an oncology trial. Chapter 5 is devoted to address the patient heterogeneity issue
in dose-finding studies using sequential designs. We propose a flexible multi-stage
design to identify patient-specific MTDs adjusting for either continuous or categorical
risk factors. Simulations are performed to illustrate the benefit of using this risk-
adjusting design under various scenarios.
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Chapter 2
Review of dose finding studies
2.1 Continual reassessment method
CRM was first introduced by O’Quigley et al. [20] as a model-based sequential
method for dose finding studies. The basic idea of CRM is to assume a simple one-
parameter dose-toxicity model, and repeatedly estimate the dose-toxicity curve with
cumulated data collected from sequentially enrolled patients. The method appeals to
clinicians because it attempts to treat the next patient at the current best estimate of
the target dose [26], and has received much attention in the medical community [24;
18].
2.1.1 Basic components
We first describe the Bayesian version of the method. In a typical dose finding
study, we observe a pair of data (xi, yi) on the i’th patient enrolled in the trial, for
i = 1, . . . , N , where xi denotes the dose assigned to the patient i, and yi denotes
the binary toxicity indicator of the patient. The choice of dose xi is confined to
a discrete panel of dose levels, d1, . . . , dK . Dose finding is often formulated as a
percentile estimation problem, that is, for a pre-specified probability θ, we aim to
identify ν = arg mink |π(dk) − θ|, where π(x) = pr(yi = 1 | xi = x) is the true
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probability of toxicity at dose x [7]. CRM approximates π(x) through a dose-toxicity
function F (x, β) indexed by a single parameter β. The main idea of the method is
to treat the next patient at a dose with a toxicity probability estimated to be closest
to the target θ. Specifically, it sets xi+1 = arg mindk |F (dk, β̂Bi )− θ|, where β̂Bi is the
posterior estimate of β based on observations from the first i patients. The process
is repeated until a pre-specified sample size N is reached.
An important point about the CRM is that the dose labels d1, . . . , dK are not the
actual doses administered, but are values re-scaled to a domain that is compatible
with the prior inputs to the model. More precisely, the dose label dk is obtained by
matching an initial guess of toxicity probability p0k for the dose k using the dose-
toxicity function F (x, β) under the prior model-based estimate β̂B0 , that is, setting
p0k = F (dk, β̂
B
0 ) where β̂
B
0 denotes the prior mean of β. The set of initial guesses
{p0k} is sometimes called the ‘skeleton’. Ideally the skeleton is chosen based on
clinical inputs to reflect the initial beliefs of the toxicity probability associated with
the test doses. In practice, such information is rarely available from the clinical
investigators, and as a result, if we believe ν0 is the maximum tolerated dose level a
priori, we will set p0ν0 = θ, so that the starting dose x1 = dν0 with F (x1, β̂
B
0 ) = θ.
Different skeletons may lead to very different operating characteristics. To avoid the
subjectivity in the specification of a particular skeleton, Yin and Yuan [31] proposed
specifying multiple skeletons, each representing a set of prior estimates of the toxicity
probabilities. Using the Bayesian model averaging to even out the contributions of
multiple skeletons into the sequential estimation procedure, this avoids the potential
bias caused by only using one specific skeleton. Another pragmatic approach is to
treat each p0k as a model parameter and tune it so that CRM will yield good average
operating characteristics [7]. However, this tuning problem can be a daunting task as
there are K parameters in the skeleton and each has infinitely many possible values.
As an alternative to the Bayesian approach, O’Quigley & Shen proposed us-
ing maximum likelihood estimate in conjunction with CRM [21]. The idea is to
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treat each subsequent patient at the model-based MTD xi+1 = ν̂i where ν̂i :=
arg mindk |F (dk, β̂i)−θ| and β̂i is the maximizer of the likelihood based on the first i ob-
servations. Since the likelihood approach does not require specification of prior distri-
bution of the model parameters, it addresses the perceived subjectivity of its Bayesian
counterpart discussed previously. However, for a one-parameter dose-toxicity func-
tion F , since β̂i exists if and only if there is heterogeneity in the toxicity outcomes
in the first i observations, the trial requires an initial dose escalating sequence {xi,0}
to determine dose assignments until β̂i exists. Thus, a likelihood approach implies
the use of a two-stage design, defined as xi+1 = xi+1,0 if Yj = 0 for all j ≤ i, and
xi+1 = ν̂i if Yj = 1 for some j ≤ i. As a result, a two-stage likelihood design allows
starting a trial at the lowest dose level which also addresses the safety concern raised
in one-stage Bayesian designs.
The idea of a two-stage design has been examined extensively by simulation [11;
13; 15]. In addition, Shen and O’Quigley [27] studied the large sample properties
of the likelihood CRM and showed that it consistently estimates the MTD even
when the assumed dose-toxicity model is incorrectly specified. Despite the theoretical
advantages, the actual usage of a two-stage likelihood CRM is still quite limited
primarily due to its complexity. First, as we no longer have a prior distribution of
β, neither β̂B0 nor ν0 is available in the specification of the dose labels as described
in the backward substitution procedure mentioned above. While Cheung 2011 [7]
proved that MLE is invariant to the choice of the initial value β̂0 for a given dose-
toxicity model, the role of the prior maximum tolerated dose ν0 remains unclear in
the likelihood approach. Second, the choice of the initial design sequence {xi,0} in
practice is often ad hoc and lacks systematic orientation.
In finite sample setting, the choice of CRM design parameters can be crucial to its
operating characteristics. First, it is quite plausible to specify a skeleton that can lead
to pathological and poor design performance [27; 8]. Second, an unexamined choice
of the initial dose sequence will cause dose escalations that are ethically unacceptable
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(i.e., incoherent)[6]. Lastly, there is a lack of discussion on how to choose a dose-
toxicity function. Overall, we need a systematic exposition on how to determine two-
stage CRM design parameters given certain clinical objective and sample size. In the
following chapters of this dissertation, in addition to solving the theoretical problems
remaining in the two-stage likelihood CRM, we will also propose calibration algorithm
to facilitate the choice of the design parameters to achieve satisfying performance.
2.1.2 Indifference interval and calibrated skeleton
CRM is proven to be consistent under certain model mis-specification but not
generally. Cheung and Chappell (2002) found that certain models with inappropriate
initial guess of dose toxicities can lead to pathological behavior. Suppose dose k is
the MTD, an indifference interval associated with this dose level k can be defined
as an interval θ ± δk, within which, the toxicity probability of dose k will eventually
fall into when the sample size is sufficiently large (δk denotes the half-width of the
indifference interval). δk specifies the minimal distance in toxicity probability from
dose k to its neighboring doses such that the doses can be correctly differentiated
given a large enough sample size. For a specific CRM design, the indifference interval
δ is defined as the union of the indifference intervals for each of the target doses
ν ∈ {2, . . . , K − 1}. CRM is said to have equi-indifference intervals if the length of
the indifference interval is the same for all ν = 2, . . . , K − 1.
While tuning for all K parameters p0k’s is quite computationally extensive, Lee
and Cheung (2009) developed an algorithm to calibrate the entire skeleton using only
two parameters under the Bayesian framework. Given the prior belief that dose level
ν0 is the MTD, thus p0,ν0 = θ, the algorithm specifies the choice of {p0k : k 6= ν0}
to CRM with equi-indifference interval of δ. Using this algorithm, we only need to
specify ν0 and δ to construct a calibrated skeleton that guarantees the design would
eventually select a dose with toxicity probability that falls within the interval of θ±δ.
This algorithm reduces the number of model parameters from K to 2 for constructing
CHAPTER 2. REVIEW OF DOSE FINDING STUDIES 14
the skeleton.
The half-width indifference interval δ indicates the design resolution in large sam-
ple setting, i.e., the minimum distance of the target dose from its neighboring doses
so that this target dose can be correctly selected as the MTD. This in turn can be
used as a design tuning parameter to facilitate the design calibration in finite sample
settings. A large δ value defines dose labels that are further apart from each other
on the x-axis, hence indicating a working model with a steep slope, while a small δ
value corresponds to a flat working model. In the Phase I clinical trial, we can use
a series of working model with varying steepness via specifying a range of δ values,
evaluate their model performance, and determine the optimal δ value for the given
clinical scenario.
2.1.3 Coherence
For a two-stage CRM, the choice of an initial design also impacts the trial behav-
ior. An inappropriately chosen dose-escalating sequence may lead to unethical dose
assignment [6], and whether the dose assign is ethical or not is called the design’s co-
herence property [6]. A coherent dose assignment indicates that if the current patient
experiences toxicity, the probability of dose escalation on the next patient is zero, i.e.,
pr(xi − xi−1 > 0 | yi−1 = 1) = 0. Incoherence means the opposite. During the first
stage, without toxicity, the dose escalation follows a non-decreasing dose escalation
sequence, and thus, is coherent. The model-based dose assignment using CRM is also
proven to be coherent [6]. However, Cheung (2005) pointed out that the transition
point from first stage to the second stage during a two-stage trial may not be coher-
ent, i.e., the first model-based dose assignment after observing the first toxicity is not
necessarily coherent when the initial design is not chosen appropriately. In fact, an
overly conservative (slow) initial design will cause incoherence in a two-stage CRM.
Although incoherence in a two-stage design is a single point problem, which can
only occur on the first model-based dose assignment upon observing the first toxicity,
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the complexity of this problem is that it is unknown where the first toxicity would
occur during a dose-finding study using sequential design. If a two-stage trial enrolls
a total of N patients, presumably there are up to N different scenarios where the first
toxicity could occur, and a two-stage CRM is called coherent only if it is coherent
across all N scenarios.
The first part of this dissertation is intended to introduce a unified framework
to build a coherent two-stage CRM using likelihood approach. A comprehensive
calibration algorithm will be proposed and recommendations on design parameters
under various clinical scenarios will be made based on this framework.
2.2 Dose finding studies with patient heterogene-
ity
2.2.1 O’Quigley’s two-group CRM
O’Quigley et al. [22; 19] proposed two-parameter CRM models to identify group-
specific MTDs for patients belonging to high and low risk groups simultaneously in
a single trial. In addition to the parameter indicating the slope of the dose-toxicity
curve, another model parameter is introduced to represent the group effect on the
dose-toxicity curve. Below is the two-parameter empiric function:
F (yi = 1|xi = dk : zi) = dexp(a+bzi)k
with yi, xi, zi indicating binary toxicity outcome, assigned dose level, and risk group
(zi = 1 high risk and zi = 0 low risk for instance) for each patient, respectively. The
assigned dose level xi takes a value of dk (k = 1, . . . , K). Both groups share the same
K dose levels. The group effect is represented by b, and when b = 0, it indicates there
is no group difference, and all patients in both groups have the same toxicity tolerance
and thus share the same MTD. In real trial setting, even though we acknowledge the
group difference, we might not know which group has higher tolerance. In their first
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paper in 1999, O’Quigley et al. [22] assumed no prior knowledge on the magnitude
and direction of the difference between the two risk groups, and employed a two-stage
design. An arbitrary initial design was installed to allow independent dose escalation
in each group. Once the first toxicity is observed in one group, the usual one-sample
CRM F (yi = 1|xi = dk) = dexp(a)k will be used to assign the dose to the next patient
of the same group, and the dose escalation in the other group will still follow the
initial design. Once toxicities are observed in both risk groups, all data are pooled
to fit the two-parameter CRM model and model-based dose assignment will proceed
within each group.
O’Quigley and Paoletti [19] modified this two-group CRM design by incorporating
the prior knowledge on direction of the difference between the two risk groups. First,
instead of allowing independent dose escalation between the two risk groups during
initial design, the patients belonging to the low risk group are always assigned at
a dose level greater than or equal to the current dose level in the high risk group,
because low risk group is supposed to have higher drug tolerance level according to
the prior knowledge. Such initial design allows skipping doses in one group (low
risk group) but not the other (high risk group). However the escalation rule is still
arbitrarily determined. Second, Bayesian method was used to estimate parameters
a and b, with non-informative prior for a and normal prior for b with mean µb and
standard error σb. µb and σb can be determined to reflect the uncertainty on the
magnitude or even direction of the ordering between the two risk groups.
2.2.2 Bivariate isotonic design
Ivanova and Wang [14] proposed a bivariate isotonic design for ordered risk groups.
In addition to satisfy the assumption of non-decreasing dose-toxicity relationship
within a group, i.e., p̂j1 ≤ · · · ≤ ˆpjK , where j = 1, 2 indicating the risk group,
the dose-toxicity probability estimates are also subject to between group constraint
p̂2k ≤ p̂1k, k = 1, . . . , K, if group 2 is believed to have lower toxicity rate than group
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1, and vice versa. If no prior knowledge is available on ordering of risk groups, the
squared difference between bivariate isotonic estimates and observed dose-toxicity
probabilities are computed under both scenarios and the constrained estimator with













jk is the result of bivariate isotonic regression estimate, assuming group 2 has
higher tolerance to toxicity. In case M (1,2) = M (2,1), the univariate isotonic estimate
of toxicity is obtained from the combined sample. The dose allocation rule for the
next patient is as follows: stay on current dose if the estimated toxicity probability
of the current dose is within θ ± ∆, and escalate/de-escalate if otherwise, where ∆
is a design parameter. Without prior knowledge on group orderings, the trial starts
with two independent initial designs similar to the one used in O’Quigley et al. 1999
[22]. With known group orderings, the design uses the informative initial design
in O’Quigley and Paoletti 2002 [19]. After toxicity is observed, the trial proceeds
following the dose allocation rule based on the bi-variate isotonic estimate.
2.2.3 Escalation with overdose control (EWOC)
Babb and Rogatko proposed EWOC method in 1998 [2]. The method controls the
overdose probability during the sequential design using CRM. Comparing to the stan-
dard CRM which chooses a dose with minimum absolute distance to target toxicity
rate, EWOC essentially chooses a dose via minimizing a risk function that has asym-
metric weights on overdose and underdose, i.e., a risk function that has more stringent
control on overdose probability. In their 2001 paper [3], they extended EWOC to guide
individualized dosing for dose-finding study, given continuous risk-modifying factor
and continuous dose. In the clinical example illustrated in the paper, the patient’s
individual tolerance to the experimental drug PNU is modified by endogenous plasma
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anti-SEA antibody concentration due to its neutralizing effect on the experimental
drug. Higher anti-SEA concentration is associated with higher tolerance and higher
dose. A two-parameter logistic model was used to model continuous dose (x) and
anti-SEA level (c), in relation to toxicity probability prc(x).
logit[prc(x)] = α + β ln(x) + δ ln(c)
It is assumed that β > 0 and δ < 0, so that the probability of DLT is an increasing
function of dose and a decreasing function of anti-SEA concentration. The MTD can
be expressed as a function of anti-SEA concentration c and denoted as γ(c), which
results in toxicity probability equal to θ = 0.1. After observing data from the first
i patients, the next optimal dose xi+1(c) is determined such that the overdose prob-
ability, i.e., the probability of assigning a dose greater than anti-SEA concentration
adjusted MTD, is less than a pre-specified threshold value 1−ω. The real trial exam-
ple designed using this method show that patients with high baseline anti-SEA have
robust tolerance to high doses of the experimental drug PNU.
2.2.4 Other model-based designs
Piantadosi and Liu [23] proposed to incorporate the pharmacokinetics parameter
in the CRM model to improve the dosing accuracy, and employed a bivariate logistic
dose-toxicity model as shown below. In addition to dose, a continuous covariate:
∆AUC , is included into the model. ∆(AUC) is the difference between estimated
pharmacokinetics parameter area under curve (AUC) and the observed AUC, which
is considered ancillary to dose administered.
logit(pr(dose,∆AUC)) = β0 − β1 × dose− β2 ×∆AUC
The method imposes a joint uniform prior distribution on the two parameters. After
obtaining their posterior estimates, the optimal dose to be assigned to the next patient
can be solved by inserting the parameter estimates into the above formula and setting
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the predicted difference (δAUC) at zero, i.e., dosei+1 = (β̂0i− logit(π))/β̂1i, where π is
the target toxicity probability.
Thall et al. [29] extended the dose finding method based on toxicity-efficacy trade-
off to account for additional covariate effect. The method imposes an informative
prior on covariate effect parameters obtained from preliminary fit of historical data
and a non-informative prior on dose-toxicity model parameter. Putting aside the
model complexity due to bivariate endpoints, the model on the toxicity endpoint for
patients observed during the trial is
logit(pr(x, Z)) = f(x, α) + βZ + xγkZ
This model is more complex because it not only has the main effect terms of
dose f(x, α), covariate βZ, but also the interaction term between dose and covariate
γkZ. For cytotoxic agent, the main dose effect can be specified as linear function
f(x, α) = α0 + α1x where α1 > 0 indicating that toxicity probability increases as
dose x increases. The prior distribution of covariate effect β is obtained from analysis
on the historical data. In contrast, the method keeps the prior of (α0, α1, γ) as non-
informative since they are associated with the effects of the experimental dose. In the
application example, the authors grouped the continuously measured covariate into
high, medium and low risk groups before applying the method.
2.3 Limitations of existing methods
Bayesian approach has many advantages and been widely adopted in clinical trial
designs. However it is still perceived as subjective compared to MLE. As illustrated in
the papers dealing with two risk group design [21; 22; 14], mis-specified priors on the
group ordering parameters may slow down the algorithm convergence, or even lead
to incorrectly determined MTD. In more complicated designs such as dose finding
with multiple risk groups, more parameters need cautious justification on their prior
distributions. The computational complexity is also a prominent issue with Bayesian
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method. Non-informative priors are usually considered equivalent to MLE, however,
the computation could be much more intensive than MLE.
MLE avoids subjectivity and is often computationally economical, but requires
an initial design to specify dose escalation before heterogeneous toxicity outcome
occurs and model based method is activated. Dose escalation without observing
toxicity outcomes is subject to ethical constraint that has two operationally conflicting
guidelines. Escalation is expected to proceed cautiously and not to overshoot the
target and put an unacceptably large number of patients at risk for toxic side effects.
Meanwhile, it is also desired to avoid treating too many patients at levels so far below
the target that the probability of seeing any treatment benefit is almost negligible.
The initial designs adopted in the reviewed literature [21; 22; 14] follow an arbitrary
escalation rule without sufficient justification from these perspectives.
Bivariate isotonic design is difficult to be extended to deal with continuous risk
factor. A more fundamental problem with this type of curve-free design is “rigidity”,
as pointed out by Cheung [5]. Due to lack of shared information across doses, when
target toxicity probability is low, the curve-free design may be confined to a low
dose and never escalate no matter how many more non-toxic outcomes observed.
A dose-finding study incorporating patient heterogeneity would likely deal with low
toxicity rate in one or multiple risk groups, suggesting the curve free method maybe
inefficacious for such purpose.
O’Quigley’s two-group CRM [22] and Thall’s individualized dosing on bivariate
outcome [29] deal with the categorical covariates. These methods can be extended
to multiple risk groups, which work for risk factors that are naturally measured in
discrete form such as heavily pre-treated versus treatment-naive patients. However,
it cannot be immediately applied on continuous risk factors as most newly identified
laboratory biomarkers through genomic or proteiomic studies. Oftentimes investiga-
tors may have knowledge on whether and how a biomarker influences patient drug
tolerance but reluctant to group the patients into high risk or low risk groups based
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on a specific cut-off value. In small sample study, information preservation by keeping
variable continuous and not dichotomizing it could potentially enhance design per-
formance. In such situation, it is desirable to develop a design that has the flexibility
to adjust for both continuous and categorical covariates.
Two-parameter EWOC [2] deals with both continuous dose and continuous co-
variate (anti-SEA concentration) using two-parameter parametric model. However,
the method is difficult to be generalized and adopted by other studies as it requires
much effort to specify the design parameters for each individual study.
The existing designs reviewed in this chapter deals with the risk factors that are
known to have effect on toxicity probability and incorporates this knowledge into the
design. However, the designs are less flexible in handling the opposite situation where
the risk factor turns out not affect the toxicity outcome in a particular trial. We will
propose a multi-stage design that evaluates the effect of risk factor on the toxicity
probability as trial goes on, and only allows adjusting individual risk factor when the
effect is evident.
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Chapter 3
Design components for two-stage
Likelihood CRM
To fully specify a two-stage likelihood CRM, we need to determine 1) a dose esca-
lating sequence {x0,i} in the first stage (initial design) to dictate the dose assignments
for initially enrolled patients before any DLT is observed, and 2) a working model to
be used to guide the dose escalation in the second stage, whereas the model parame-
ter β can be repeatedly estimated using accumulated data collected in the sequential
experiment to provide updated estimate on dose toxicity probabilities. Furthermore,
to fully specify a working model in the second stage, we need to determine, firstly the
dose-toxicity function to be used to approximate the true dose-toxicity relationship,
along with the initial value for the slope parameter β, i.e., β0, and the initial estimate
of toxicity probability on each dose level, i.e., p0k. With these initial values, the dose
labels can be determined using backward substitution and the sequentially collected
observed data can be used to obtain the updated model parameter estimate, which
then can be further used to obtain the updated model based estimates of dose toxicity
probabilities at each dose level.
In this chapter, we will characterize each of the three design components under
our proposed framework. We will start from the two design components required in
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the second stage model based design: dose-toxicity functions and specification of the
initial estimate of the dose toxicity probabilities, and then we will focus on how to
choose appropriate initial design. Theoretical results will be derived.
3.1 The Dose-toxicity model
3.1.1 ψ-equivalent functions
The CRM models the dose-toxicity relationship by a one-parameter function
F (., β). The two commonly used dose-toxicity models in the CRM literature are
the empiric function
F (x, β) = xexp(β) for 0 < x < 1
and the one-parameter logistic function
F (x, β) =
exp(a0 + βx)
1 + exp(a0 + βx)
for −∞ < x <∞
with a fixed intercept a0; see [9; 13; 21] for example. Other functions often consid-
ered include a hyperbolic tangent function [20] and a one-parameter logistic function
with a fixed slope [27].
Since the use of one-parameter function is not common in other statistical ap-
plications, the theory in this area is quite scattered. In this article, we provide a
systematic study of the following class of dose-toxicity functions in the context of the
CRM:
Consider the class of one-parameter functions
F (x, β) = ψ {c(β)h(x)}
where ψ, c, h are known functions that are strictly monotone [7].
This class includes the most commonly used dose-toxicity functions such as the em-
piric function and a one-parameter logistic function in the dose-finding literature [12].
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For example, the empiric function can be expressed as F (x, β) = exp{exp(β) log(x)},
with ψ(·) = exp(·), c(·) = exp(·), and h(·) = log(·).
Suppose that we can specify a skeleton {p0k} and an initial parameter value β̂0 so
that the dose labels dks are obtained by solving p0k = F (dk, β̂0) = ψ{c(β)h(x)}, and
dk = h(x) = ψ
−1/c(β0). Then, the dose-toxicity model can be rewritten as







which does not depend on the function h(x). Furthermore, Theorem 4.1 in [7] shows
that, for a given skeleton {p0k}, the maximum likelihood CRM is invariant among the
dose-toxicity functions represented by the same ψ function, regardless of the choice
of c(·) and β̂0. Hence, we can arbitrarily set c(β) = exp(β) and β̂0 = 0 without loss of







Two dose-toxicity functions are said to be ψ-equivalent if they can be represented
by the same ψ. For example, consider one-parameter logistic function with fixed
slope a, Fa(x, β) = {1 + exp(−β− ax)}−1. Since the function class {Fa(x, β) : a > 0}
can be represented with ψ(z) = z/(1 + z) that is free of a, all functions in this
class are ψ-equivalent. It is immediately clear how the ψ-representation offers great
simplification in the model calibration problem; in the above example, for instance, it
suffices to consider Fa for a given and arbitrary choice of a. In addition, it allows us
to systematically expand the scope of the dose-toxicity functions for the CRM. Other
functional forms for modeling binary outcome such as complementary log-log and
probit functions can be conveniently summarized using this representation. Table 3.1
lists some commonly used dose-response models.
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with intercept a 1− e− exp(az) 1− e− exp(a+eβ [log{1−log(1−p0k)}−a])
with fixed slope 1− e−z 1− (1− p0k)exp(β)
Logistic
with intercept a (1 + e−a−z)−1
exp[a+eβ{lgt(p0k)−a}]
1+exp[a+eβ{lgt(p0k)−a}]
with fixed slope (1 + z−1)−1 exp(β)p0k1−p0k+exp(β)p0k
Probit








lgt(p) = log{p/(1− p)}; Φ is the cumulative distribution function of standard normal.
3.1.2 The skeleton and the irrelevance of ν0
For a given ψ-class dose-toxicity function with c(β) = exp(β) and β̂0 = 0, skeleton
{p0k} can be specified using an algorithm described in [7]: After specifying ν0 and δ,
set p0ν0 = θ, p0k can be determined recursively such that the skeleton satisfies
ψ−1(p0,k+1)ψ
−1(θ − δ) = ψ−1(p0k)ψ−1(θ + δ) for k = 1, . . . , K − 1. (3.3)
Since ψ is strictly monotone, the skeleton thus obtained is unique and strictly
increasing. Algorithm (3.3) requires the specification of δ, the half-width of the
design’s indifference interval [8]; that is, the design will converge with probability one
to a dose with toxicity probability falling onto the interval θ ± δ. While δ, as an
asymptotic design resolution, is only interpretable given large sample size, it can also
serve as a design parameter in finite sample setting to be tuned to achieve satisfying
design operating characteristics. Lee & Cheung [16] propose a numerical algorithm
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to calibrate the skeleton p0k via tuning δ under finite sample settings.
In addition to δ, algorithm (3.3) also requires the specification of the prior maxi-
mum tolerated dose ν0. As we attempt to steer away from the Bayesian approach, the
choice of ν0 is artificial at best, and may appear subjective. Importantly, the choice
of ν0 does have an impact on the performance of the Bayesian method [7]. However,
the following Theorem holds if using maximum likelihood method.
Theorem 1. Suppose that F (x, β) and F ∗(x, φ) are ψ-equivalent functions, and
that the respective dose-toxicity models are obtained according to (3.2) with skeletons
{p0k} and {p∗0k}, that is, Fk(β) = ψ{c(β)ψ−1(p0k)} and F ∗k (φ) = ψ{c(φ)ψ−1(p∗0k)}.
Further assume that both models satisfy the regularity conditions listed in section 3.3.
(a) If, for some λ > 0,
p∗0k = ψ{λψ−1(p0k)} (3.4)
then Fk(β̂i) = F
∗
k (φ̂i) for all k, where β̂i and φ̂i be the maximum likelihood estimate
of β and φ given the observations {(xj, Yj) : j ≤ i}.
(b) If the skeletons {p0k} and {p∗0k} are generated using Algorithm (3.3) with (δ, ν0)
and (δ, ν∗0) respectively, then (3.4) holds.
Theorem 1 implies that the choice of ν0 is irrelevant in the likelihood estimate and
hence the performance of the likelihood CRM if the skeleton is chosen according to
Algorithm (3.3); hence, we can arbitrarily set ν0 = 1.
The proof of Theorem 1 and other theories developed in the following chapters
require the regularity conditions on the dose-toxicity model listed in section 3.3.
Proof of Theorem 1. By (3.4), F ∗k (φ) = ψ{c(φ)ψ−1(p∗0k)} = ψ{c(φ)λψ−1(p0k)},
whereas Fk(β) = ψ{c(β)ψ−1(p0k)}. Therefore, the two models represent re-parametrisation
of each other with c(β) = λc(φ), and the MLEs are identical, i.e., ĉ(β) = λ̂c(φ). By
invariance of maximum likelihood, we also have c(β̂i) = λc(φ̂i). The desired result in
Theorem 1(a) thus follows, i.e., Fk(β̂i) = F
∗
k (φ̂i).
To prove Theorem 1(b), consider a given dose level k. By Algorithm (3.3), we
have





















Note the equivalence in 3.5 is due to the fact ψ−1(p0ν0) = ψ
−1(p0ν∗0 ) = ψ
−1(θ) by
definition. Thus, assumption (3.4) holds.
3.2 The initial design
The primary appeal of a two-stage design is that it allows a safe starting dose,
which is usually the lowest dose level, that is, x1,0 = d1. Also since the initial design
does not prescribe de-escalation, that is, xi,0 ≤ xi+1,0, the dose sequence can be
equivalently represented by M0 = {m01,m02, . . . ,m0K}, where m0k =
∑N
i=1 I(xi,0 =
dk) is the initial cohort size of dose k and I(·) is an indicator function, such that∑K
k=1m0k = N . In practice, it is common to use equal cohort sizes for the non-
highest doses, such as, m01 = · · · = m0,K−1 = 3 with m0K = N − 3(K − 1). In order
to avoid over-conservative dosing among the earliest patients, Storer [28] suggests
that it may be reasonable to escalate relatively quickly at the start and slow down as
the trial moves to higher doses. This implies non-decreasing initial cohort sizes, that
is,
m01 ≤ m02 ≤ · · · ≤ m0,K−2 ≤ m0,K−1 ≤ m0K (3.6)
As a middle ground between equal cohort sizes and the general form of non-
decreasing cohort sizes (3.6), we focus our attention to the following class of initial
designs that allows at most one cohort size increment:
l = m01 = m02 = · · ·m0,j−1 < m0,j = m0,j+1 = · · ·m0,K−1 = l+s, and m0,K = N −m+,K−1,
(3.7)
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where m+,K−1 :=
∑K−1
k=1 m0k = l(K−1)+s(K−j) is the number of subjects needed to
escalate to the highest dose, and serves as an conservatism index of the initial design.
For the moment, assume that N is chosen so that m0,K ≥ l + s thus satisfying (3.6).
The initial design (3.7), abbreviated as a triple-indexed D0(l, s, j), allows an increase
in cohort size at most once at a dose level j ∈ {1, . . . , K − 1} by size s, and l ≥ 0 is
the cohort size for doses below j. In case when j = 1, D0(l, s, j) represents an initial
design with equal cohort sizes l+s. The design objective is thus to determine (l, s, j).
In practice, there is an inclination to choose a conservative initial design, that is, to
have a ”large” conservative index m+,K−1. On the other hand, Cheung [6] shows that
an over-conservative initial design causes incoherence in a two-stage CRM. That is,
dose escalation occurs on the next patient despite the current patient has developed
a toxicity. Therefore, a reasonable design approach is to seek the most conservative
D0(l, s, j) among all coherent initial designs in class (3.7).
Let T0 = min{i : Yi = 1} denote the index for the first patient with a toxicity.
Lemma. Suppose that a likelihood CRM is specified with ψ and {p0k} generated
according to Algorithm (3.3), so that Conditions 1–3 hold. Then if a two-stage CRM
with initial design D0(l, s, j) is incoherent, an incoherent escalation will occur with
probability one on the event {T0 = m+,K−1}. That is, xT0+1 = ν̂T0 > xT0 = xT0,0 when
T0 = m+,K−1.
Lemma holds also for any initial design M0 satisfying (3.6), and hence holds for
more general initial designs than D0 as described in (3.7).
Proof of Lemma.
Proof of Lemma. Assume without loss of generality that ψ is an increasing func-
tion, i.e., ψ′ > 0, and that ψ−1(p0k) < 0 for all k per Condition 2. For brevity, we
write ψ−1(p0k) as ψ
−1
k as shorthand expression, and develop our proof in terms of
α = exp(β).
Let u ≤ N −m+,K−1 so that xu,0 = dζ for some 1 ≤ ζ ≤ K − 1. It can be verified
that u ≤
∑ζ
k=1m0k. Suppose that an initial design M0 satisfying (3.6) induces an
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incoherent escalation on {T0 = u}, that is, xu+1 = ν̂u > xu = xu,0 upon observing
xi = xi,0 for i ≤ u and Y1 = · · · = Yu−1 = 0 and Yu = 1. We will consider two cases
in the followings:
Case 1: u <
∑ζ
k=1 m0k for ζ = 1, . . . , K − 1
Case 2: u =
∑ζ
k=1 m0k for ζ = 1, . . . , K − 2
Under Case 1, we will show thatM0 will induce an incoherent escalation on {T0 = w}
for any w > u such that xw,0 = dζ . Analogously, under Case 2, we will show that
M0 will induce an incoherent escalation on {T0 =
∑ζ+1
k=1 mk,0}. By applying these
results under Cases 1 and 2 deductively, we can then show that M0 will induce an
incoherent escalation on {T0 = m+,K−1} as desired.
First consider Case 1 when u <
∑ζ
k=1m0k. The first derivative of log-likelihood































Let α̂u denote the solution to l
′
u(α) = 0. Then the assumption that incoherence occurs
on {T0 = u} implies ψ(α̂uψ−1ζ ) + ψ(α̂uψ
−1
ζ+1) < 2θ.
Likewise, we can write the first derivative of the log-likelihood based on the first































with α̂w denoted as solution to l
′
w(α) = 0. Since
∑ζ−1
k=1m0k < u < w ≤
∑ζ
k=1m0k, the









w(α) are decreasing in α







ζ ) + ψ(α̂uψ
−1
ζ+1) < 2θ, that is, incoherence occurs on {T0 = w}.
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Analogously, under Case 2 when u =
∑ζ
k=1m0k, the first derivative of log-
























and that based on the first w =
∑ζ+1























According to (3.3), we have ψ−1k+1 = rψ
−1
k where r = ψ
−1(θ + δ)/ψ−1(θ − δ) < 1




































































































> 0 and ψ−1(p0k) < 0 by assumption, under non-decreasing cohort sizes









w(α̂w)− A(α̂w) = −A(α̂w) < 0 = l
′
u(α̂u) (3.13)
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u(α) is decreasing function











ζ ) + ψ(α̂uψ
−1
ζ+1) < 2θ. Incoherence occurs with probability one on {T0 = w}.
That is, xw+1 = ν̂w > xw = xw,0.
The Lemma assumes the skeleton is generated using Lee and Cheung’s calibration
algorithm 3.3. This Lemma provides a convenient method to check whether a two-
stage CRM is coherent for any given initial design in most general form 3.6. Since a
two-stage CRM is coherent only if it is coherent across all N scenarios of when the
first toxicity occurs, it implies that we need to exhaust all N scenarios to check for
coherence before concluding the design is coherent. With this Lemma, this task is
further reduced to checking only one scenario when the first toxicity occurs on the last
patient assigned on dose level K − 1, i.e., {T0 = m+,K−1}. Following the procedures
described in Cheung (2011), for given target toxicity rate θ, number of doses K,
dose-toxicity function ψ, and the skeleton generated using Lee and Cheung (2009)’s
approach, the likelihood estimate of model parameter β̂ can be obtained under this
specific toxicity outcome, the following inequality will be checked [8]:
ψ{exp(β̂)ψ−1K−1}+ ψ{exp(β̂)ψ
−1
K } − 2θ > 0 (3.14)
If this inequality holds, the next dose assignment is coherent under this specific
toxicity outcome profile, according to the Lemma, the two-stage CRM using this
initial design is coherent under any toxicity outcome scenario.
Theorem 2. Suppose that the assumptions in the Lemma hold, and Condition
4 also holds.
(a) For any coherent initial design D0(l, s, j), there exists a triplet (l∗, s∗ = 1, j∗),
such that D0(l∗, s∗, j∗) is also coherent, with l∗(K−1)+s∗(K−j∗) ≥ l(K−1)+s(K−j).
(b) Among all D0(l∗, s∗, j∗) in part (a), there exists a unique triplet that has the
largest m+,K−1.
Proof of Theorem 2. Similar to the proof of Lemma, we assume without loss of
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generality that ψ is an increasing function, i.e., ψ′ > 0, and that ψ−1(p0k) < 0 for all
k per Condition 2. For brevity, we write ψ−1(p0k) as ψ
−1
k as shorthand expression,
and develop our proof in terms of α = exp(β).
Suppose an initial designD0(l, s, j) is coherent with conservatism index n0 = l(K−
1)+s(K−j), and also that D0(l+1, s, j) is coherent with n1 = (l+1)(K−1)+s(K−j).
It is obvious that n1 > n0. Likewise, suppose that D0(l, s, j − 1) is coherent with
conservatism index n2 = l(K − 1) + s(K − j + 1), thus n2 > n0. To complete
the proof of Theorem 2(a), we will only need to consider a “boundary” coherent
initial design D0(l, s, j) with conservatism index n0, such that D0(l + 1, s, j) and
D0(l, s, j − 1) are incoherent; and prove that for this triplet (l, s, j), there exists a
coherent D0(l∗, s∗ = 1, j∗) with
n∗ = l∗(K − 1) + s∗(K − j∗) ≥ n0 (3.15)
The proof of Theorem 2(a) can then be completed by induction.
To facilitate the proof, we rewrite the first K − 1 cohort sizes of an initial design




, ω) = {l′ + q1, l
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and qK−1−q1 = s or 0. ω and s
′
are non-negative integers. It is clear that for given








, ω) are identical. Precisely,




= s, ω = K− j, and q1 = q2 = . . . = qj−1 = 0
and qj = qj+1 = . . . = qK−1 = s.














, ω̄ + 1) = D(l, s, j − 1). For given (l, s), the conservatism index of a
boundary sequence D0(l, s, j) equals to n0 = l
′





, ω) is coherent}.






























, ω) belongs to the class of initial design
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(3.7) with only cohort size increment 1.













, ω) have the same conservatism index l
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, ω) is coherent}. Then for given l′ and s′ , if we can show that ω̄ ≤ ω1, it













, ω1 + 1) is incoherent, then the
desired results follows from the definition of ω̄.




, ω1 + 1) is incoherent on the event









, ω1 + 1) = {l
′
+ q1, . . . , l
′
+ q1}, i.e., qK−1 − q1 = 0. In this case,




, ω1 + 1) = {l
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+ q1, . . . , l
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+ q1} = D0(l′, s
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, ω1 + 1) = {l
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+ q1, . . . , l
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+ qK−1} with qK−1 − q1 = 1.In this
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, ω1+1) is also incoherent.




, ω1 + 1) = {l
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+ q1, . . . , l
′
+ qK−1}




2, . . . , q
′
K−1, such that E0(l
′
, s′, ω1 + 1) =





qK−1 − q1 =
K−2∑
k=1
















k ≥ 0, 1 ≤ k ≤ K − 2
With at most one cohort size increment in both D̄0 and E0, there exists a J , such
that qJ − qJ−1 = s and qk+1 − qk = 0 for 1 ≤ k ≤ K − 2 and k 6= J . Likewise, there
also exits a J
′








k = 0 for 1 ≤ k ≤ K − 2 and
k 6= J ′ .
If q
′
1 < q1, without loss of generality q
′





, ω1+1) is q1∗(K−1)+s(K−J
′
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K−1 > qK−1, without loss of generality q
′





, ω1 + 1) is qK−1 ∗ (K − 1)− s ∗ (J





, ω1 + 1) is qK−1 ∗ (K − 1) + (K − J), contradicting the fact that their
conservatism index are identical. Thus, q
′
K−1 ≤ qK−1.
Since q1 ≤ q′1 ≤ q′K−1 ≤ qK−1, for 1 ≤ k ≤ K − 1, there exists a k∗, such that
qk ≤ q
′
k when 1 ≤ k < k∗, and qk ≥ q
′
k when k





, ω1 + 1), the first derivative with respect to α of the












































Define α̂E0 such that l
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K ) < 2θ




, ω1 + 1). When the first toxicity occurs on {T0 =











































































k − qk). By the
assumptions of ψ
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, 1 ≤ j ≤ i ≤ K




D̄0(α). In addition, l
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, ω1), belong to class (3.7) with s = 1 that is
more conservative than the ”boundary” sequence D0(l, s, j).
Next we prove part(b) of Theorem 2. Suppose D0(l∗, s∗ = 1, j∗) is coherent with
n∗ = l∗(K − 1) + K − j∗ ≥ n0. if D0(l∗, s∗ = 1, j∗) is not a boundary sequence, we
then check coherence of D0(l∗+ 1, s∗ = 1, j∗) or D0(l∗, s∗ = 1, j∗− 1) until we identify
the boundary sequence. If D0(l∗, s∗ = 1, j∗) is a boundary sequence,then it is the
most conservative and coherent initial design.
Next we show that, given we identify the boundary sequence with the largest
conservatism index n∗ = l∗(K − 1) + (K − j∗), there exists a unique pair (l∗, j∗)
such that the boundary sequence D0(l∗, s∗ = 1, j∗) has conservatism index n∗ =
l∗(K − 1) + (K − j∗). Suppose there are two pairs (l∗1, j∗1) and (l∗2, j∗2) and both yield
the same conservatism index. Without loss of generality, assuming l∗1 = l
∗
2 +1, we have
l∗1(K−1)+K−j∗1 = (l∗2+1)(K−1)+K−j∗1 = l∗2(K−1)+K−j∗2 +(j∗2−j∗1 +K−1). Since
1 ≤ j∗1 , j∗2 ≤ (K− 1), 1 ≤ (j∗2 − j∗1 +K− 1) ≤ (2K− 3), we have l∗1(K− 1) +K− j∗1 ≥
l2(K−1)+K−j∗2 +1, which contradicts the assumption. Therefore, such pair (l∗, j∗)
is unique.
Theorem 2 implies the unique existence of a most conservative coherent initial
design among all D0(l, s, j), for given ψ and {p0k}. As a consequence of the proof of
Theorem 2, this design can be attained by setting s = 1 and iterating (l, j) according
to the following algorithm:
CHAPTER 3. DESIGN COMPONENTS FOR TWO-STAGE LIKELIHOOD CRM36
1. Initialize l = 0 and j = K − 1.
2. If D0(l, s, j) is coherent, update j = j−1 if the current j > 1; and set j = K−1
and l = l + 1 if the current j = 1.
3. If D0(l, s, j) is incoherent, stop iterating.
The last coherent D0(l, s, j) before stopping the iteration will be the most conservative
coherent initial design.
3.3 Regularity conditions
The following assumptions are commonly made for dose-toxicity models used with
the CRM, and they can be verified for each ψ considered in Table 3.1 with {p0k}
generated according to Algorithm (3.3).
Condition 1. ψ{exp(β)ψ−1(p0k)} is strictly increasing in k for all β.
This is true for all ψ class functions.
Condition 2. ψ{exp(β)ψ−1(p0k)} is monotone in β in the same direction for all k.
In Table 3.1, empiric/hyperbolic tangent, complementary log-log with sufficiently
large positive fixed intercept, logistic with sufficiently large positive fixed intercept,
and probit with sufficiently large positive fixed intercept are decreasing in β. The
other ψ class functions are increasing in β.





+ (1− p) −ψ
′{exp(β)ψ−1(p0k)}
1− ψ{exp(β)ψ−1(p0k)}
is continuous and strictly monotone in β, where ψ
′{exp(β)ψ−1(p0k)} denotes the
derivative of ψ{exp(β)ψ−1(p0k)} with respect to β.







} = F ′k(β)
p−Fk(β)
Fk(β){1−Fk(β)}
. If R(β) is monotone
function in β, the function has uni-root at zero. Next we show it is monotone for
each ψ class function.
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Empiric/hyperbolic tangent: F
′









. Since Fk(β) is decreasing on β and log(dk) < 0, R(β)
is decreasing on β.
Logistic with fixed intercept a0: F
′
k(β) = Fk(β){1 − Fk(β)} exp(β)dk < 0 for
sufficiently large positive a0. R(β) = exp(β)dk{p− Fk(β)}. Since Fk(β) is decreasing
on β and dk < 0, R(β) is decreasing on β.
Logistic with fixed slope:F
′
k(β) = Fk(β){1 − Fk(β)}. R(β) = p − Fk(β). Since
Fk(β) is increasing on β, R(β) is decreasing on β.
Complementary log-log with fixed intercept a0:F
′
k(β) = {1 − Fk(β)}[− log{1 −
Fk(β)}] exp(β)dk < 0, with sufficiently large positive a0 such that dk < 0. R(β) =
log{1−Fk(β)}{p−Fk(β)}
Fk(β)
exp(β)(−dk) = log{1−Fk(β)}{ pFk(β)−1} exp(β)(−dk). Since Fk(β)
is decreasing on β, both log{1 − Fk(β)} and pFk(β) − 1 are increasing functions of β.
−dk is positive. Therefore R(β) is increasing on.
Complementary log-log with fixed slope:
Probit with fixed slope:F
′










k(β) = Fk(β) logFk(β) < 0. gij(β) = Fj(β) logFj(β){1−







> 0. Since 0 < Fβ(x) < 1, logFβ(x) < Fβ(x) − 1 on interval
0 < Fβ(x) < 1. Thus, m
′
(x) is increasing on x, and gij(β) > 0.
Logistic with large positive fixed intercept a0: F
′
k(β) = Fk(β){1−Fk(β)} exp(β)dk =
Fk(β){1−Fk(β)}{logitFk(β)−a0} < 0. gij(β) = {Fj(β){logitFj(β)−a0}−Fi(β){logitFi(β)−





β(x){logitFβ(x) + 11−Fβ(x) − a0}. Since F
′
β(x) > 0, and when a0 is sufficiently
large,m
′
(x) < 0. Thus, {Fj(β){logitFj(β) − a0} − Fi(β){logitFi(β) − a0}} > 0 for
j < i.gij(β) > 0.
Logistic with fixed slope has been shown in the Chapter 4 of [7].
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Complementary log-log with fixed intercept a0: F
′
k(β) = {1 − Fk(β)}[− log{1 −
Fk(β)}](log[− log{1 − Fk(β)}] − a0) < 0 for sufficiently large positive a0. gij(β) =
(log{1−Fi(β)}(log[− log{1−Fi(β)}]− a0)− log{1−Fj(β)}(log[− log{1−Fj(β)}]−
a0)){1−Fj(β)}{1−Fi(β)}. Suppose m(x) = log{1−Fβ(x)}(log[− log{1−Fβ(x)}]−
a0), m
′




(log[− log{1− Fβ(x)}]− a0 + 1) > 0. Thus, m
′
(x) is increasing
on x, and gij(β) > 0.
Complementary log-log with fixed slope: F
′
k(β) = −{1−Fk(β)} log{1−Fk(β)} >
0. gij(β) = [log{1− Fi(β)} − log{1− Fj(β)}]{1− Fi(β)}{1− Fj(β)}. Since log{1−
Fβ(x)} is decreasing in x, gij(β) < 0.
Probit with fixed slope: F
′
k(β) = φ{β + Φ−1(p0k)} > 0. Let the quantiles zk =
Φ−1(p0k) and zi > zj. gij(β) = φ(β + zj){1 − Φ(β + zi)} − φ(β + zi){1 − Φ(β +







< 0. Thus, gij(β) < 0.
Probit with fixed intercept a0: F
′
k = φ{a0 + exp(β)dk} exp(β)dk < 0, with suf-
ficiently large positive a0. gij(β) = φ{−(a0 + eβdj)}djΦ{−(a0 + eβ)} − φ{−(a0 +
eβdi)}diΦ{−(a0 +eβdj)}. Let zi = −(a0 +eβdi), zj = −(a0 +eβdj), thus zi < zj. gij =
φ(zj)(−zj−a0)Φ(zi)−φ(zi)(−zi−a0)Φ(zj) = φ(zi)(zi+a0)Φ(zj)−φ(zj)(zj+a0)Φ(zi).







< 0 when a0 is sufficiently
large positive. Hence m(x) is decreasing function of x. Thus, gij(β) > 0.
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Chapter 4
Design calibration and application
With large sample size, CRM converges to the doses with toxicity probability
falling within a window around the target rate θ. The half width of this window is
defined as the model sensitivity parameter δ [8]. However, with finite sample size,
it is important to calibrate the design parameters to achieve satisfying performance.
As discussed in previous Chapter, three design components may influence the design
performance of two-stage likelihood CRM: initial design D0, dose-toxicity function ψ,
and initial estimate of the dose toxicity probabilities, “skeleton”, (p0k). Theorem 2
reveals that the most conservative and coherent initial design can be determined for
given ψ and skeleton. From Theorem 1, skeleton can be determined for given model
sensitivity parameter δ. We propose a semi-automatic calibration algorithm which
iterates over a range of δ values, for given ψ, and evaluates the performance using
average accuracy across a set of true dose-toxicity profiles [16; 7]. This procedure can
be repeated for each ψ function to compare across different ψ.
4.1 Calibration algorithm
For given target toxicity rate θ, number of doses K, and total number of patients
N , we first specify one of the ψ functions listed in (3.1), then apply the following
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calibration algorithm:
• Step 1: Vary δ in a range between 0.01 to 0.7×θ by step size of 0.01 [16]. For
each δ, do step 2-5:
– Step 2: determine skeleton {p0k} using Algorithm (3.3) based on δ and
ν0 = 1.
– Step 3: Given (ψ, p0k), obtain the most conservative coherent D0(l∗, 1, j∗)
according to the algorithm in Chapter 3.
– Step 4: Specify λ and calculate the number of patients to be tested on the
highest dose level mK = λ/θ. The initial design obtained in step 3 will
be pruned down with respect to is constraints and total sample size N ,
according to Algorithm 10.2 in [7].
– Step 5: Simulate 2000 trials with the fully specified two-stage likelihood
CRM (ψ, p0k,D0), under K dose toxicity scenarios described using the
plateau configurations with an odds ratio of 2 [16]. Record the recom-
mended MTD in the end of each trial. Calculate the average probability
of correct selection (PCS) across the K scenarios.
• Step 6: Choose the δ value which yields the maximum average PCS. The corre-
sponding design parameters (p0k,D0) will be the recommended design parame-
ters, for the specific ψ.
In practice, the number of patients to be reserved on the highest dose level K is
usually determined separately as by the time the trial escalates to the highest dose
level dK without observing any toxicity, the highest dose is the one closest to the
pre-specified target toxicity rate and it is preferred to test more patients on this dose
level before claiming it as MTD. Usually λ = 1, 1.2, 1.5, 2, . . . [7] and its specific value
can impact the pruning of the initial design, hence the design performance.
This calibration algorithm can be repeated for each ψ function, and the respective
plot of average PCS versus δ can be generated to compare across the ψ functions.
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4.2 Redesign the NeuSTART trial
As described in the introduction section, NeuSTART is a dose finding trial that
aims to determine the maximum tolerated dose for lovastatin in stroke patients [10]
with θ = 0.1 and K = 5. The original trial design was the two-stage Bayesian
CRM with design parameters described in the introduction Chapter. This design was
calibrated by the trial-and-error approach [7].
We re-design NeuSTART using the likelihood CRM with the dose-toxicity func-
tions listed in (3.1). The design parameters are determined based on algorithms
described above, as follows. For each ψ, we first calculate the skeleton {p0k} using
algorithm (3.3) for δ ranging from 0.01 to 0.05 with increment of 0.0025; For each
pair (ψ, δ), we obtain the most conservative coherent D0(l∗, 1, j∗) according to the
algorithm in Chapter 3. In our study design we also set m05 = 12 with N = 33,
such that sufficient number of subjects would be tested at the highest dose if there
were no toxicity throughout. In order to make the calibrated designs comparable to
the original study design, we “prune” D0(l∗, 1, j∗) using Algorithm 10.2 in [7] with
respect to the constraint m05 = 12 and N = 33 while keeping the pruned design
coherent. For each completely specified design (ψ, δ,D0), we ran simulations under
K dose toxicity scenarios described as the plateau configurations with an odds ratio
of 2 [16]. Table 4.1 gives, for each ψ, the calibrated design that maximises the aver-
age probability of correctly selecting ν in the K scenarios. In addition, Figure (4.2)
displays the average probability of correct selection by (ψ, δ): the average accuracy
reaches maximum either at δ = 0.0275 or at δ = 0.0175; and, the difference in the
average accuracy is less than 1% when δ lies between 0.0175 and 0.0275. It gives
some assurance that the design performance is insensitive to the choice of δ over this
range, thus rendering the choice of “optimal” δ quite robust.
The performance of these calibrated designs are compared to the NeuSTART
study design under the toxicity scenarios listed in Table 4.1 using simulation with
5,000 replicates. Table 4.3 shows that all designs give comparable average probability
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of correct selection. Also, all the calibrated designs lead to slightly better performance
than the NeuSTART design when ν is at the highest dose—a rather common clinical
expectation a priori. Finally, this simulation study confirms that, for finite sample
settings, the CRM is robust against the choice of the dose-toxicity function as long
as the design parameters are well calibrated. In particular, it suggests and justifies
the use of the most commonly used empiric function.
4.3 Two-stage design for the oncology trial
As described in the introduction, the goal of this oncology trial is to identify MTD
among 5 dose levels with either 2-way or 3-way drug combinations of Gemcitabine,
Cabazitaxel and Cisplatin, for treating bladder cancer patients. The MTD combi-
nation will be estimated using a two-stage Bayesian CRM. In the first stage, a rule
based design will be used. Once a DLT is observed, we will switch to the second
stage using the CRM. There are several advantages of the CRM compared to con-
ventional designs. First, the CRM has been shown to have better performance than
the 3+3 design and treat fewer patients at suboptimal doses. Second, it allows for
the specification of a fixed sample size for the trial. Third, it assigns a dose after the
outcome of every patient is observed. The advantage of using a two-stage CRM over
a one stage-CRM is it starts at the lowest dose, like conventional designs. This is
desired because of safety concerns in starting with the combination of all three drugs
for intravesical use. Thus, the design is expected to be more conservative than the
one stage CRM and outperform the 3+3 design in selecting the correct dose as the
MTD.
The specified sample size is 24 patients using a cohort size of one. The first
patient will be assigned dose level 1 (2g of Gemcitabine and 2.5mg of CAB). Before
a DLT is observed, dose escalation will follow the dose sequence listed in Table 4.4.
Once a DLT is observed, dose escalations will be determined using a Bayesian CRM.
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Figure 4.1: Average probability of correct selection versus δ for each ψ-class functional
form.
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The CRM with an empirical dose-toxicity model and a normal prior distribution on
the parameter with mean 0 and variance of 0.55 will be used [17]. The expected
MTD is dose level 3. The dose-toxicity model is calibrated such that the method
will eventually select a dose that yields between 20% and 30% DLT [16; 8]. The
design will not allow for dose skipping and dose escalation immediately after a DLT
is observed [6].
The operating characteristics of our design under different various scenarios are
displayed in the table 4.5. With 24 patients, the design selects the correct MTD
with probabilities over 50% in all five scenarios, outperforming the conventional 3+3
design. The scenarios where selected to have neighborhood doses with DLT rates
within 10-15% of the MTD rate. If the neighboring doses have DLT rates significantly
different from the target of 25%, the probability of correct selection will be improved.
A stopping rule will be implemented whereby if the first two patients experience
toxicity the trial will be stopped for toxicity.
4.4 Comprehensive simulation results
Extensive simulations are performed in this section to recommend the optimal
design parameter δ under a wide range of clinical scenarios that are commonly en-
countered in practice [16]. The target toxicity probability considered for typical dose-
finding studies are 0.10, 0.20, 0.25, and 0.33, the sample sizes are 25, 30, 35, and 40,
and the number of doses ranges from 4 to 7. The dose-toxicity model is assumed to be
empiric function. Two thousand simulations were performed under each scenario and
no dose skipping during the dose escalation/de-escalation is allowed. The calibration
algorithm introduced in the previous section is used to make recommendations on
the optimal δ for each scenario. Tables 4.6,4.7,4.8,4.9 display the δ that yields the
highest average PCS, the corresponding pruned initial design, and the average PCS.
Another design parameter λ is specified at either 1 or 2. For θ = 0.10, these indicates
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the number of patients reserved to be tested on the highest dose level is 10 and 20
respectively. Larger λ requires more pruning on the initial design, thus allows more
aggressive dose escalation and yields higher accuracy (Table 4.6).
The optimal δ ranges between 0.02 and 0.04 for θ = 0.10, 0.03-0.04 for θ = 0.20,
0.04-0.06 for θ = 0.25, and 0.05-0.07 for θ = 0.33. These results are comparable to
the calibration results of one-stage CRM [16]. The optimal δ increases as the target
rate increases, and decreases as number of doses increases and number of patients
increases.
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Table 4.1: Calibrated design parameters for the likelihood CRM for NeuSTART, with
θ = 0.10, K = 5, m05 = 12, and N = 33.
ψ δ Skeleton according to (3.3) Initial Design, M0
p01 p02 p03 p04 p05 D0(l∗, 1, j∗) Pruned
Empiric .0275 0.10 0.16 0.24 0.33 0.42 6,6,7,7,7 4,5,6,6,12
Complementary log-log
with fixed intercept=1 .0275 0.10 0.17 0.25 0.34 0.43 6,6,7,7,7 4,5,6,6,12
with fixed intercept=3 .0175 0.10 0.14 0.19 0.25 0.32 4,4,5,5,15 4,4,5,5,15
with fixed intercept=5 .0175 0.10 0.14 0.19 0.26 0.33 4,4,5,5,15 4,4,5,5,15
with fixed slope .0275 0.10 0.17 0.29 0.47 0.68 6,6,7,7,7 4,5,6,6,12
Logistic
with fixed intercept=1 .0275 0.10 0.16 0.24 0.31 0.38 6,6,7,7,7 4,5,6,6,12
with fixed intercept=3 .0275 0.10 0.17 0.25 0.35 0.45 6,6,7,7,7 4,5,6,6,12
with fixed intercept=5 .0175 0.10 0.14 0.19 0.25 0.31 4,4,5,5,15 4,4,5,5,15
with fixed slope .0275 0.10 0.17 0.28 0.42 0.58 6,6,7,7,7 4,5,6,6,12
Probit
with fixed intercept=1 .0275 0.10 0.16 0.23 0.31 0.38 6,6,7,7,7 4,5,6,6,12
with fixed intercept=3 .0175 0.10 0.14 0.18 0.24 0.29 4,4,4,5,16 4,4,4,5,16
with fixed intercept=5 .0275 0.10 0.17 0.25 0.35 0.45 6,6,7,7,7 4,5,6,6,12
with fixed slope .0175 0.10 0.14 0.19 0.25 0.32 4,4,5,5,15 4,4,5,5,15
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Table 4.2: True dose toxicity probability scenarios for validation in the NeuSTART
trial.
Scenarios Validation sets
p1 p2 p3 p4 p5
1 .10 .25 .30 .35 .40
2 .04 .10 .25 .30 .35
3 .01 .04 .10 .25 .30
4 .01 .01 .04 .10 .25
5 .01 .01 .01 .04 .10
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Table 4.3: Operating characteristics of the calibrated designs and NeuSTART design
under the scenarios in Table 4.2.
Designs PCS (%) for each scenario
1 2 3 4 5 Average
NeuSTART
Bayesian 88 54 55 53 65 63.00
Likelihood 86 52 54 54 67 62.66
Empiric 87 53 56 45 73 62.67
Complementary log-log
fixed intercept=1 87 53 54 47 72 62.63
fixed intercept=3 87 44 45 47 75 59.75
fixed intercept=5 87 46 46 43 76 59.66
with fixed slope 89 51 48 46 71 61.06
Logistic
fixed intercept=1 86 54 56 46 73 62.82
fixed intercept=3 87 53 53 46 73 62.31
fixed intercept=5 87 45 45 47 75 59.79
with fixed slope 89 51 49 47 71 61.27
Probit
fixed intercept=1 86 54 56 46 72 62.94
fixed intercept=3 86 46 47 49 73 60.18
fixed intercept=5 87 53 54 47 72 62.45
with fixed slope 87 45 45 47 75 59.79
PCS is probability of correct selection
CHAPTER 4. DESIGN CALIBRATION AND APPLICATION 49
Table 4.4: Calibrated initial design for the oncology trial.





9 to 24 5mg 100mg
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Table 4.5: Operating characteristics of the calibrated design for the oncology trial.
Method MTD below level 1 1 2 3 4 5
0.25 0.35 0.50 0.65 0.80
3+3 Design 0.44 0.36 0.18 0.02 0.00 0.00
Two-Stage CRM 0.07 0.60 0.30 0.03 0.00 0.00
0.15 0.25 0.40 0.55 0.70
3+3 Design 0.21 0.34 0.33 0.11 0.01 0.00
Two-Stage CRM 0.03 0.22 0.53 0.21 0.01 0.00
0.10 0.15 0.25 0.40 0.55
3+3 Design 0.10 0.19 0.30 0.30 0.10 0.02
Two-Stage CRM 0.01 0.03 0.25 0.51 0.19 0.01
0.03 0.07 0.15 0.25 0.40
3+3 Design 0.01 0.06 0.17 0.36 0.29 0.10
Two-Stage CRM 0.00 0.00 0.03 0.27 0.52 0.19
0.01 0.03 0.07 0.15 0.25
3+3 Design 0.00 0.01 0.05 0.17 0.32 0.46
Two-Stage CRM 0.00 0.00 0.00 0.05 0.31 0.65
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Table 4.6: Recommended design parameters for OR = 2 and θ = 0.10.
K N λ δ pruned D0 average PCS
4 25 1 0.03 (4,5,6,10) 45.95
2 0.04 (1,2,2,20) 46.94
30 1 0.02 (5,5,6,14) 47.38
2 0.03 (2,4,4,20) 48.75
35 1 0.02 (5,5,6,19) 49.59
2 0.03 (4,5,6,20) 50.54
40 1 0.02 (5,5,6,24) 52.3
2 0.02 (5,5,6,24) 52.3
5 25 1 0.03 (3,3,4,5,10) 40.11
2 0.03 (1,1,1,2,20) 41.04
30 1 0.03 (4,5,5,6,10) 41.16
2 0.04 (2,2,3,3,20) 43.19
35 1 0.02 (5,5,5,5,15) 43.38
2 0.04 (3,3,4,5,20) 45.19
40 1 0.02 (5,5,5,5,20) 45.71
2 0.03 (4,5,5,6,20) 45.72
6 25 1 0.04 (2,2,3,4,4,10) 36.6
2 0.03 (1,1,1,1,1,20) 36.88
30 1 0.02 (3,3,4,5,5,10) 37.38
2 0.04 (1,1,2,3,3,20) 39.77
35 1 0.02 (4,4,4,5,5,13) 39.16
2 0.02 (2,2,3,4,4,20) 41.23
40 1 0.02 (4,4,4,5,5,18) 41.43
2 0.02 (3,3,4,5,5,20) 42.43
7 25 1 0.04 (2,2,2,2,3,4,10) 33.53
2* – – –
30 1 0.04 (3,3,3,3,4,4,10) 33.54
2 0.04 (1,1,1,1,3,3,20) 36.31
35 1 0.02 (3,4,4,4,5,5,10) 35.71
2 0.03 (2,2,2,3,3,3,20) 37.67
40 1 0.02 (4,4,4,4,5,5,14) 37.29
2 0.02 (3,3,3,3,4,4,20) 38.7
*:Non-valid initial designs under all δ values.
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Table 4.7: Recommended design parameters for OR = 2 and θ = 0.20.
K N λ δ pruned D0 average PCS
4 25 1 0.04 (2,3,3,17) 54.45
2 0.04 (2,3,3,17) 54.45
30 1 0.04 (2,3,3,22) 57.05
2 0.04 (2,3,3,22) 57.05
35 1 0.04 (2,3,3,27) 60.18
2 0.04 (2,3,3,27) 60.18
40 1 0.04 (2,3,3,32) 62.9
2 0.04 (2,3,3,32) 62.9
5 25 1 0.04 (2,2,2,3,16) 48.45
2 0.04 (2,2,2,3,16) 48.45
30 1 0.04 (2,2,2,3,21) 50.8
2 0.04 (2,2,2,3,21) 50.8
35 1 0.04 (2,2,2,3,26) 53.9
2 0.04 (2,2,2,3,26) 53.9
40 1 0.04 (2,2,2,3,31) 56.61
2 0.04 (2,2,2,3,31) 56.61
6 25 1 0.03 (1,2,2,2,2,16) 44.13
2 0.03 (1,2,2,2,2,16) 44.13
30 1 0.03 (1,2,2,2,2,21) 46.74
2 0.03 (1,2,2,2,2,21) 46.74
35 1 0.03 (1,2,2,2,2,26) 50.02
2 0.03 (1,2,2,2,2,26) 50.02
40 1 0.03 (1,2,2,2,31) 52.7
2 0.03 (1,2,2,2,31) 52.7
7 25 1 0.03 (1,1,1,2,2,2,16) 40.71
2 0.03 (1,1,1,2,2,2,16) 40.71
30 1 0.03 (1,1,1,2,2,2,21) 43.81
2 0.03 (1,1,1,2,2,2,21) 43.81
35 1 0.03 (1,1,1,2,2,2,26) 46.74
2 0.03 (1,1,1,2,2,2,26) 46.74
40 1 0.03 (1,1,1,2,2,2,31) 49.93
2 0.03 (1,1,1,2,2,2,31) 49.93
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Table 4.8: Recommended design parameters for OR = 2 and θ = 0.25.
K N λ δ pruned D0 average PCS
4 25 1 0.06 (2,2,3,18) 56.14
2 0.06 (2,2,3,18) 56.14
30 1 0.04 (2,2,2,24) 59.91
2 0.04 (2,2,2,24) 59.91
35 1 0.05 (2,2,2,29) 62.76
2 0.05 (2,2,2,29) 62.76
40 1 0.04 (2,2,2,34) 64.93
2 0.04 (2,2,2,34) 64.93
5 25 1 0.04 (1,1,2,2,19) 51.19
2 0.04 (1,1,2,2,19) 51.19
30 1 0.04 (1,1,2,2,24) 55.02
2 0.04 (1,1,2,2,24) 55.02
35 1 0.04 (1,1,2,2,29) 57.76
2 0.04 (1,1,2,2,29) 57.76
40 1 0.04 (1,1,2,2,34) 60.52
2 0.04 (1,1,2,2,34) 60.52
6 25 1 0.04 (1,1,1,2,2,18) 46.71
2 0.04 (1,1,1,2,2,18) 46.71
30 1 0.04 (1,1,1,2,2,23) 50.84
2 0.04 (1,1,1,2,2,23) 50.84
35 1 0.04 (1,1,1,2,2,28) 53.97
2 0.04 (1,1,1,2,2,28) 53.97
40 1 0.04 (1,1,1,2,2,28) 56.1
2 0.04 (1,1,1,2,2,28) 56.1
7 25 1 0.04 (1,1,1,1,2,2,17) 42.89
2 0.04 (1,1,1,1,2,2,17) 42.89
30 1 0.04 (1,1,1,1,2,2,22) 47.19
2 0.04 (1,1,1,1,2,2,22) 47.19
35 1 0.04 (1,1,1,1,2,2,27) 49.99
2 0.04 (1,1,1,1,2,2,27) 49.99
40 1 0.04 (1,1,1,1,2,2,32) 52.24
2 0.04 (1,1,1,1,2,2,32) 52.24
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Table 4.9: Recommended design parameters for OR = 2 and θ = 0.33.
K N λ δ pruned D0 average PCS
4 25 1 0.06 (1,1,2,21) 59.91
2 0.06 (1,1,2,21) 59.91
30 1 0.07 (1,2,2,25) 63.69
2 0.07 (1,2,2,25) 63.69
35 1 0.06 (1,1,2,31) 66.04
2 0.06 (1,1,2,31) 66.04
40 1 0.05 (1,1,2,36) 68.14
2 0.05 (1,1,2,36) 68.14
5 25 1 0.07 (1,1,2,2,19) 53.73
2 0.07 (1,1,2,2,19) 53.73
30 1 0.06 (1,1,1,2,25) 57.38
2 0.06 (1,1,1,2,25) 57.38
35 1 0.05 (1,1,1,1,31) 60.58
2 0.05 (1,1,1,1,31) 60.58
40 1 0.05 (1,1,1,1,36) 62.84
2 0.05 (1,1,1,1,36) 62.84
6 25 1 0.05 (1,1,1,1,1,20) 49
2 0.05 (1,1,1,1,1,20) 49
30 1 0.06 (1,1,1,1,2,24) 52.44
2 0.06 (1,1,1,1,2,24) 52.44
35 1 0.06 (1,1,1,1,2,29) 55.68
2 0.06 (1,1,1,1,2,29) 55.68
40 1 0.05 (1,1,1,1,1,35) 58.29
2 0.05 (1,1,1,1,1,35) 58.29
7 25 1 0.05 (1,1,1,1,1,1,19) 45.04
2 0.05 (1,1,1,1,1,1,19) 45.04
30 1 0.05 (1,1,1,1,1,1,24) 48.11
2 0.05 (1,1,1,1,1,1,24) 48.11
35 1 0.05 (1,1,1,1,1,1,29) 51.69
2 0.05 (1,1,1,1,1,1,29) 51.69
40 1 0.05 (1,1,1,1,1,1,34) 54.27
2 0.05 (1,1,1,1,1,1,34) 54.27
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Chapter 5
CRM with continuous risk factor
The study objective of conventional dose-finding design is usually to identify a
common MTD associated with per-specified target toxicity rate for all patients. In
such studies we may run into the problem of substantial patient heterogeneity. A
typical example in cancer studies is that heavily pre-treated patients tend to have
less tolerance to drug toxicity, compared to treatment naive patients. Extensions
of standard design have been proposed to deal with heterogeneity: some sought to
identify MTD for discrete number of risk groups [21; 22; 14], others used fully param-
eterized models to identify patient specific MTD for continuous risk factor, but the
methods are difficult to generalize and adapt to a different trial. We propose a risk
adjusting design using a flexible multi-parameter model to identify patient specific
MTD among a discrete set of doses, and the patient heterogeneity can be indicated
by either continuous or discrete risk factor. The method in the following sections is
developed for continuous risk factor, but can be conveniently applied on discrete risk
factor.
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5.1 Design objective
The design objective is to evaluate the effect of a risk factor (continuous or dis-
crete) on dose toxicity probabilities, and when the effect is evident, the trial will
adjust for the risk factor in dose allocation and identify the patient-specific MTD:
ν(z) = argmin
k
|F (dk, z)− θ|, {k : k = 1, . . . , K}. where z denotes the continuous risk
factor.
The following notations will be used throughout this chapter to describe the clin-
ical setting and statistical models: Suppose a dose-finding trial has K dose levels and
enrolls N patients sequentially. For the i’th patient enrolled in the trial, xi is the
dose assignment and yi is the binary toxicity outcome. Specifically, xi is confined to
a discrete set of values, xi = dk, k = 1, . . . , K, and dk indicates the k’th dose level.
The patient’s risk factor value is represented using zi, with z0 a specified reference
level for this continuous risk factor. Model parameter γ indicates the effect size of
the risk factor on toxicity probability. Model parameter αk is the intercept of the
covariate-toxicity curve at the reference covariate value z0, for the k’th dose level.
The true covariate-toxicity relationship is represented using the the most common
logistic regression model, with a single continuous risk factor z and k dose levels. We
assume a linear function for covariate effect and non-parametric form for dose effect,
except that the toxicity probabilities are non-decreasing with dose levels for given
covariate z. Assuming there is no interaction effect between covariate z and dose
level dk, this model can be represented using the following K + 1-parameter model.
logit{Fk(z|αk, , γ)} = {αk + γ(z − z0)} (5.1)
where α1 ≤ α2 . . . ≤ αK . Fk(z) is the toxicity probability given dose level k and z.
When the patient population are homogeneous, because either all patients have
the same covariate value or the risk factor z does not have modifying effect on toxicity
probability (γ = 0), the product term on the right hand side of the equation becomes
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a constant, the model reduces to
logit{Fk(z|αk)} = αk (5.2)
The k + 1-parameter model (5.1) can be viewed as K parallel covariate-toxicity
curves, and each curve has a common “slope” γ and different “intercept” αk.
This true regression model (5.1) is also the working model to be used in the trial
design in the following sections.
5.2 Trial design
Presumably a risk-adjusting design is preferred when there is a plausible biolog-
ical mechanism for patient heterogeneity in drug tolerance. For example, CYP3A4
metabolises irinotecan, hence varying level of CYP3A4 activity modifies the individ-
ual’s toxicity probability. However, we do not expect such effect to be prominent
in every trial; thus, one should not assume the risk adjusting design is necessary at
the beginning of a trial. Instead, it would be useful to evaluate the risk effect using
the initially accumulated data, and only incorporate the individual risk level into the
dose allocation when the risk effect becomes evident in the patients enrolled in this
specific trial. If there is a lack of the risk effect during the trial, a conventional design
is sufficient to serve the purpose.
To achieve such flexibility in dealing with patient heterogeneity, the trial will pro-
ceed in two stages: In the beginning, the trial will be conducted using the conventional
design as if all patients are exchangeable in terms of risk in developing DLT. When
sufficient data are available, a testing procedure will be used to examine the effect
of risk factor z on toxicity probabilities. When the risk effect is significant enough
and exceeds a pre-specified threshold, the second stage, risk adjusting stage, will be
activated. During the risk adjusting stage, the K + 1-parameter model (5.1) will be
fitted using all data after each new patient is treated, and the parameter estimates
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will be updated to guide the risk adjusted dose assignment for the next patient.
Exchangeable stage: We use the two-stage likelihood CRM developed in chapter
3 during this stage. While all patients enrolled in the trial are treated exchangeably
in terms of individual susceptibility to drug toxicity, the trial will start from the
lowest dose level and the initial dose escalation follows a pre-specified rule (initial
design D0). Upon observing the first DLT, model based design will be activated and
the dose assignments will follow a conventional one-parameter CRM model with a
single parameter β modeling the dose-toxicity relationship, such as the one-parameter
logistic function.
Using ψ representation, the working model is
logit{Fk(β)} = {exp(β)/ exp(β0)logit(p0k)} (5.3)
MLE will be used to obtain the parameter estimate β̂. Therefore initial values
of design parameters do not impact the design performance [7]. β0 can be set to 0
and p0k can be determined by the algorithm (3.3) given a design parameter δ. Using
the calibration algorithm in chapter 4, the design parameters in this stage including
model sensitivity parameter δ and the most conservative and coherent initial design
D0 can be determined given the clinical parameters. The dose assignment for the






For ethical reason, we allow no more than one dose level escalation or de-escalation
at any time during the exchangeable stage.
Switching condition: As more data are cumulated during the exchangeable
stage, we may be able to start to test the presence of the patient heterogeneity by
fitting k+ 1-parameter model 5.1 on the data, and evaluate the risk effect estimate γ̂
and the significance level. However, certain conditions are required to obtain a valid
estimate of γ̂ using the k + 1-parameter model.
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Condition 1: Toxicity outcome heterogeneity is observed on at least one dose level.
Condition 2: Among the dose levels that satisfy condition 1, there exists non-
perfect partition of covariate z by toxicity outcome on at least one of them.
If we denote mk as the number of patients who are treated on dose level k and
tk as the number of them develop toxicity, then condition 1 is equivalent to that
there exists at least a k, k ∈ {k : mk > 0}, such that 0 < tk < mk. Condition 2
is equivalent to that among all the dose levels that satisfy condition 1, there exists
at least a k, such that min{zi : xi = dk, yi = 1} < max{zi : xi = dk, yi = 0}, and
min{zi : xi = dk, yi = 0} < max{zi : xi = dk, yi = 1}, i = 1, . . . , N .
Once these two conditions are met, we will fit the k + 1-parameter model to
obtain γ̂ and determine if the effect is strong enough to switch to the next stage,
risk-adjusting design. Assuming i− 1 patients have been treated in the exchangeable
stage, and both conditions are met, we can obtain γ̂ by maximizing the conditional
likelihood function [4]. Let j be the running index to denote the j’th patient from
the total of i− 1 patients treated thus far, and I(.) be an indicator function, the full
likelihood is





j=1 yjI(xj = dk){αk + γ(zj − z0)}]∏K
k=1
∏i−1
j=1 [1 + exp{αk + γ(zj − z0)}]
I(xj=dk)
The sufficient statistics for αk is
∑i−1
j=1 yjI(xj = dk), for k = 1, . . . , K. The




j=1 yj(zj − z0)I(xj = dk).
Let tk,i−1 =
∑i−1
j=1 yjI(xj = dk), which indicates the total number of toxicities
occurred on dose level k after i − 1 patients are treated. The conditional likelihood















indicates summation of the summand over all the possible sets
{yj :
∑i−1
j=1 yjI(xj = dk) = tk,i−1}.
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γ̂ is estimated by maximizing the conditional likelihood (5.5). However, this esti-
mate may be highly variable due to small number of patients tested at the beginning
of a trial, thus lead to a large p value. To conduct such a risk-adjusting dose-finding
study, we often have some knowledge about the covariate effect while planning for the
trial, where at least we could anticipate the direction of the effect estimate. Therefore
we adopt one-sided test instead of two-sided test to evaluate the strength of the risk
effect on toxicity probability. If the one-sided p value is sufficiently small and less than
a pre-specified threshold p∗, the trial will switch to the risk-adjusting stage where the
subsequent dosing algorithm will take into account the individual risk z. Otherwise,
the trial proceeds in exchangeable stage, where β̂ in the regular one-parameter model
(5.3) will be updated using the i− 1 patients and dosing algorithm (5.4) will be used
to determine the dose level for the next patient. Meanwhile, k + 1-parameter model
will be re-fitted to obtain γ̂ each time a new patient is enrolled and treated, and the
switching condition will be re-examined to determine when the trial will switch to
the next stage.
We use Wald test statistic based on the asymptotic normality of γ̂ to derive the
one-sided p value. A trial would switch to the risk-adjusting stage only if the observed
covariate effect aligns with the prior knowledge and is evident enough. When an
opposite effect is observed, the trial will continue in the exchangeable stage because
of the uncertainty of the risk effect due to the conflict with the prior knowledge.
Risk-adjusting stage: When the switching condition is satisfied, i.e., the one-
sided p value drops below a threshold value p∗, the trial will switch to the next stage
and adjust for the individual risk factor. At this point, toxicity outcome heterogeneity
has been observed on at least one dose level, and possibly on multiple dose levels.
While it is possible that higher dose level(s) have not yet been assigned with any
patients, each of the lower dose levels should have been assigned with at least one
patient, due to the no dose skipping rule from the exchangeable stage. In other words,
we expect to test at least one patient on each of the consecutive dose levels starting
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from the lowest one.
For these consecutive dose levels each with at least one assigned patient, the cor-
responding covariate-toxicity curve intercept αk can be estimated given the recently
updated γ̂. Assuming a total of i− 1 patients enrolled and treated after entering the
risk adjusting stage, the full likelihood is





j=1 yjI(xj = dk){αk + γ̂(zj − z0)}]∏K
k=1
∏i−1
j=1 [1 + exp{αk + γ̂(zj − z0)}]
I(xj=dk)









exp{αk + γ̂(zj − z0)}
1 + exp{αk + γ̂(zj − z0)}
]
= 0 (5.6)
where k ∈ {k : 0 < mk, k = 1, . . . , K}, and mk =
∑i−1
j=1 I(xj = dk) and γ̂ is the
solution that maximizes the conditional likelihood (5.5).
To obtain the estimates of αk under the non-decreasing constraint, we first obtain
α̃k, which are the solutions to the equations (5.6). Specifically, α̃k equals to a finite
value when heterogeneous toxicity outcomes are observed on k’th dose level, i.e.,
k ∈ {k : 0 < mk, k = 1, . . . , K, and 0 < tk < mk}; α̃k equals to −∞ when no patient
developed toxicity on this dose level, i.e., k ∈ {k : 0 < mk, k = 1, . . . , K; and tk = 0};
α̃k equals to ∞ when all patients developed toxicities on this dose level, i.e., {k : 0 <
mk, k = 1, . . . , K and tk = mk}.
The solutions α̃k will be examined for violations of the non-decreasing constraint
between any neighboring pairs. When a violation occurs, we will apply the pool-
adjacent-violator algorithm (PAVA) [1] iteratively, until the updated estimate α̂k
satisfies the non-decreasing constraint, i.e., α̂1 ≤ α̂2 ≤ . . . ≤ α̂K , where {k : 0 <
mk, k = 1, . . . , K}.
To illustrate the calculation of α̂k following the aforementioned procedure, a snap-
shot of patient level data at the end of a simulated trial with K = 5 and N = 40 is
listed in Table 5.1. The data are grouped by dose levels, and both the covariate value
and toxicity outcome for each patient is listed. Through maximizing the conditional
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likelihood on this set of data, we obtain γ̂ = −3.5 and the associated one-sided p
value 0.027. Table 5.2 lists summary statistics for the patient level data in Table
5.1: number of assigned patients mk and observed toxicities tk on each dose level; the
corresponding raw estimate (α̃) and the constraint estimate (α̂). Since zero toxicity
occurs on dose level 1 and 5, α̃1 = α̃5 = −∞; the estimates on the rest of the dose
levels take finite values due to the heterogeneous outcome. Because α̃4 > α̃5, violating
the non-decreasing constraint, the patient level data on these two dose levels were
pooled together to obtain the updated estimates α̂4 = α̂5 = −0.86. Since there is
no further violation of the constraint among the updated estimate, they serve as the
final estimate of the intercept parameters.
Dose assignment algorithm: Similar to the dose assignment algorithm in the
exchangeable stage, the dose with toxicity probability closest to the target rate will
be assigned to the next patient in the risk adjusting stage. However, the dose toxicity
probabilities not only vary by doses but also depend on patient specific risk level, the
one dimensional search problem becomes two dimensional, with an additional factor
z. ν(z) = argmin
k
|F (dk, z)− θ|, {k : k = 1, . . . , K}.
After estimating the parameters γ̂ and α̂k, the entire covariate-toxicity curve can
be constructed by inserting these estimates into the k + 1-parameter model (5.1)
for each of the consecutively tested dose levels {k : 0 < mk, k = 1, . . . , K}. The
toxicity probability at covariate z on dose level k is estimated as F̂k(z|γ̂, α̂k) =
exp{α̂k+γ̂(z−z0)}
1+exp{α̂k+γ̂(z−z0)}
. To determine the optimal dose for a newly enrolled i’th patient
with covariate zi, a set dose toxicity probability estimates can be read off the esti-
mated covariate-toxicity curves at z = zi, : {p̂k(z = zi), k = 1, . . . , K}. To determine
the dose assignment for this specific patient with covariate zi, we only need to concern
this panel of cross-sectional values instead of the entire covariate-toxicity curves, and
the decision becomes a one-dimensional problem.
However, the covariate-toxicity curves for some dose levels may not be distinguish-
able or even available, if the trial has not proceeded far enough to collect sufficient
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data. Particularly, two or more adjacent dose levels will have identical estimated
covariate-toxicity curves after applying PAVA. When there are multiple doses with
risk adjusted toxicity probability equally close to the target toxicity rate θ, denoted
as Ci = {k : |p̂k(z) − θ| ≤ |p̂j − θ|, j 6= k, j, k ∈ 1, . . . , K} and the estimated toxic-
ity probability p̂k(z) for this set is higher than the target toxicity rate θ, we would
consider the lowest dose in this set to be the most “likely” correct dose, because
potentially the lower dose may be differentiated from the rest and be the single dose
that is closest to the target rate should more data be collected. Likewise, we consider
the highest dose in this set to be the more “likely” correct dose when the estimated
probability p̂k(z) is lower than θ. In summary, the most “likely” dose is defined as
below, for the
ν̂(zi) =
 min{Ci(zi)} if p̂Ci(zi) ≥ θ,max{Ci(zi)} if p̂Ci(zi) < θ (5.7)
Figure 5.1 demonstrates an example where dose 1 and 2 share the same estimated
covariate-toxicity curve, dose 3 and 4 share the same covariate-toxicity curve, and
estimate on dose 5 is not available as trial has not escalated to the highest dose level
yet. With any given covariate z value, the set of point estimates on these curves at
z can be extracted and plotted separately as a function of dose. For a finite number
of doses, a dose-toxicity curve appears as a step function with at most K steps if
the estimates on all dose levels are available and distinguishable. As shown in Figure
5.2, the step function has only two steps as there are only two distinguishable dose
toxicity estimates from the five dose levels. The fifth dose level is not estimable and
indicated with a circle and labelled as“NA” on the step function. Since the cross-
sectional estimate of dose toxicity probabilities is also a function of covariate value z,
the position of the dose-toxicity curve (the step function) relative to the same target
toxicity rate θ vary depends on the input of z. If the newly enrolled i’th patient has a
relatively low tolerance level due to the low expression level of the metabolic enzyme,
i.e., zi = 3.35 as shown in the upper left graph of Figure 5.2, dose 1 and 2 are the
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closest to the target rate. As both doses still appear more toxic than expected as they
yield higher toxicity probability than the target rate θ, according to the algorithm
5.7, dose 1 will be assigned to this patient. With higher covariate value, a patient is
able to tolerate higher dose level. Consequently, dose level 2 and 3 would be assigned
if z is sufficiently large (the upper right and middle left graphs in Figure 5.2).
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Table 5.2: Estimating α using simulated data in 5.1 with N = 40,K=5, z0 = 3.44, and
γ = −4. The conditional logistic regression yields γ̂ = −3.5 and p=0.027.
nk 1 12 14 2 2
tk 0 1 7 1 0
α̃k −∞ -2.74 -1.04 -0.61 −∞
α̂k −∞ -2.74 -1.04 -0.86 -0.86
The dose assignment algorithm is more complicated for patient tolerating higher
doses (high z value) as the decision may involve dose level(s) with unavailable toxicity
estimate. As shown in Figure 5.1, dose 5 is not available because either the trial has
not escalated to it or the dose is too toxic and the trial had finished at a lower dose.
This is problematic when both dose 3 and 4 are the closest doses to θ and their
estimate is below θ. According to definition 5.7, dose 4 should be the recommended
dose. However, we cannot rule out the possibility that dose level 5 is the most “likely”
dose just because data is not available to estimate its toxicity probability. There is a
higher chance that dose level 5 is the most “likely” one if the estimate p̂(z)3 = p̂(z)4
is too far below θ. We further incorporate “acceptable probability range” to facilitate
the decision making in such situations. The recommended dose from the estimable set
by definition 5.7 remain the most “likely” dose if the estimated toxicity probability
falls within an symmetric window around target rate [θ − h, θ + h]; otherwise, the
immediate next dose level outside the estimable set is the most “likely” dose. Suppose
h = 0.05, the middle right and bottom left graphs in Figure 5.2 illustrate that patients
with relatively large covariate values z = 3.80 and z = 3.95 are assigned dose levels 4
and 5, respectively, using this “acceptable probability range” approach. This dosing
algorithm provides another level of flexibility and allows dispersion in dose assignment
to explore the more toxic doses.
Furthermore, a map can be generated to illustrate the one-to-one correspondence
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between risk factor level z and MTD. This map summarizes the dose assignment
decisions across a wide range of covariate z values, and it again appears to be a step
function (Figure 5.3). Instead of generating an individual graph for each specific z
value as in Figure 5.2, this map shows dose assignment for continuously changing
z values. One can easily identify the next optimal dose level by drawing a vertical
line with x-axis at z and the assigned dose level ν̂(z) would be the one that the line
crosses. Such map is particularly useful in the end of a trial as the final product of




The true risk effect on toxicity probability γ is chosen based on Irinotecan data
analysis in the introduction section. The multi-variable analysis on composite DLT
endpoint (grade ≥ 3 neutropenia, leukopenia or diarrhea) suggests the effect estimate
of baseline clearance level (largely determined by CYP3A4 activity level) on toxicity
is -4.07, i.e., one unit increase in log transformed baseline clearance level decreases
the odds of having any DLT by 98%. Since −4 indicates a rather steep slope of the
covariate-toxicity curve, to evaluate the design performance under varying extent of
risk effect, the true γ takes one of the following three values: -4, -2, and 0. Particularly,
γ = 0 represents no covariate effect on toxicity probability and flat covariate-toxicity
curves, for which the conventional dose-finding study for homogeneous patient pop-
ulation is deemed to be sufficient. In addition to the slope parameter (γ), the true
“intercepts” αk’s are determined via specifying the true dose toxicity probabilities at
the reference covariate value z = z0. For each γ value, K true dose toxicity profiles at
z = z0 were generated to cover from the most toxic scenario (dose level 1 has target
toxicity probability) to the least toxic scenario (dose level K has the target toxicity
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Figure 5.1: An example of estimated covariate-toxicity curves: dose 1 and 2 share the same
curve; dose 3 and 4 share the same curve; dose 5 is not available. The covariate value and
the corresponding risk-adjusted MTD for 5 example patients are labelled.
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Figure 5.2: The estimated dose-toxicity curves given the estimated covariate-toxicity curves
in figure 5.1, for z = 3.35,z = 3.55,z = 3.73,z = 3.80 and z = 3.95. The risk-adjusted dose
for each of these z values is dose level 1, 2, 3, 4, and 5, respectively.
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Figure 5.3: The step function to map the covariate range and risk-adjusted MTD, with
the same 5 examples labelled on the map.
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probability). The target toxicity rate is θ = 25%.
All fifteen true scenarios (3 γ values and K = 5 sets of dose toxicity profiles) are
illustrated in Figures 5.4,5.5,5.6. In each figure, K = 5 scenarios were generated by
setting the toxicity probabilities given z = z0 as {0.25,0.4,0.45,0.55,0.55}, {0.05, 0.25,
0.4, 0.45, 0.55},{0.05,0.05, 0.25, 0.45, 0.55}, {0.05,0.05,0.08,0.25,0.45},{0.05,0.05,0.08,0.12,0.25}
[16]. The true αk’s are derived as αk = log{pk/(1 − pk)}, where pk is the k’th dose
toxicity probability. Larger γ indicates steeper covariate-toxicity curves and stronger
risk effect on toxicity probability. Consequently, a relatively small change in covariate
z would cause shift in MTD.
5.3.2 Trial simulation and conduct
With target toxicity rate θ = 0.25 and K = 5, for each trial, we specify the total
number of patients to be enrolled N = 40, the same sample size as the Irinotecan
trial[30]. The patient level data in each trial are simulated sequentially, with the
covariate value zi ∼ N(3.44, 0.31) and toxicity tolerance score ui ∼ U(0, 1). The
mean and standard deviation of the covariate distribution are estimated based on the
distribution of the natural log transformed baseline clearance level in the Irinotecan
data set [30]. The individual true toxicity probability at any covariate zi can be
calculated using π(dk, z) =
exp{αk+γ(zi−z0)}
1+exp{αk+γ(zi−z0)}
, where αk is the corresponding true
intercept value at dose level dk in the specified true scenarios. If ui is less than the
true toxicity probability π(dk, z), the patient will experience DLT and yi=1, otherwise
yi=0.
Based on Table 4.8 in chapter 4, the design parameters in the exchangeable stage
are determined as follows: one-parameter logistic dose-toxicity function, half width of
the indifference interval δ=0.04, and the most conservative and coherent initial design
D0 = {1, 1, 2, 2, 34}. Each simulated trial starts using the same two-stage likelihood
CRM design and the trial will either switch to risk-adjusting stage or remain in
the exchangeable stage depending on whether the switching condition is met. As
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Figure 5.4: True toxicity scenarios with γ = −4, K=5, θ=0.25 (horizontal reference line).
From top to bottom on the left-hand side, the 5 true covariate-toxicity graphs represent
most toxic scenario (dose level 1 has target toxicity rate of 25% at z0 = 3.45) to the least
toxic scenario (dose level 5 has target toxicity rate of 25% at z0 = 3.45). The reference
covariate value z0 = 3.45 is labelled using a vertical reference line. From top to bottom
on the right-hand side, the step function to map covariate range and the true risk-adjusted
MTD for each scenario.
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Figure 5.5: True toxicity scenarios with γ = −2, K=5, θ=0.25 (horizontal reference line).
From top to bottom on the left-hand side, the 5 true covariate-toxicity graphs represent
most toxic scenario (dose level 1 has target toxicity rate of 25% at z0 = 3.45) to the least
toxic scenario (dose level 5 has target toxicity rate of 25% at z0 = 3.45). The reference
covariate value z0 = 3.45 is labelled using a vertical reference line. From top to bottom
on the right-hand side, the step function to map covariate range and the true risk-adjusted
MTD for each scenario.
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Figure 5.6: True toxicity scenarios with γ = 0, K=5, θ=0.25 (horizontal reference line).
The 5 true covariate-toxicity graphs represent most toxic scenario (dose level 1 has target
toxicity rate of 25% at z0 = 3.45) to the least toxic scenario (dose level 5 has target toxicity
rate of 25% at z0 = 3.45). The reference covariate value z0 = 3.45 is labelled using a vertical
reference line.
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part of the switching criteria, we specify the threshold for one-sided p value range
among 0,0.01,0.05,0.1,0.2, 0.5 and 0.75, to reflect an increasingly flexible control on
entering the risk adjusting stage. Particularly, the p value threshold 0 allows no
transition into risk-adjusting stage, hence the entire trial is carried out using the two-
stage likelihood design to identify a common MTD for homogenous study population.
Different dosing algorithm is used in different stages as described previously. When
expanding to the unexplored high dose levels during the risk-adjusting stage, the half
width of the “acceptable probability window” h = 0.05, indicating the dose with
estimated toxicity probability within θ± 5%, i.e., [20%, 30%], is ”acceptable”.
All dose assignments and toxicity outcomes for patients enrolled during the trial
are recorded. If a trial stays within the exchangeable stage at the end of the simula-
tion, the final recommended MTD is recorded. Otherwise, a final set of estimates γ̂
and α̂k will be obtained using records of all N = 40 patients.
5.3.3 Simulation results
Under each of the 15 true scenarios and each p threshold value, two thousand trials
were simulated. Table 5.3 lists the number of trials remaining at the exchangeable
stage or entered the risk-adjusting stage in the end. With very strong risk effect on
toxicity, larger proportion of trials switched to risk-adjusting stage. Trials also have
higher chance to enter the risk-adjusting stage under more toxic scenario (scenario
1) compared to less toxic scenario (scenario 5). As the design parameter p threshold
increases, an increasing number of trials is allowed to switch to the risk-adjusting
stage.
With γ = 0, i.e., no risk effect on toxicity outcome and patients are homogeneous
in terms of probability of developing toxicity, the proportion of trials ended in risk-
adjusting stage are the false positive trials. The bottom panel in Table 5.4 shows the
design’s false positive rate increases as p value threshold increases. With non-zero
risk effect (γ = −4 or -2), the proportion of trials remaining at exchangeable stage
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are the false negative trials. Apparently the false negative proportion depends on the
risk effect size. The top two panels in Table 5.4 show that the false negative rate
decreases as p value threshold becomes large. For the true effect size γ = −4, the
design with p = 0.05 yields 6-15% false negative rates and around 7-11% false positive
rates across scenarios.
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To evaluate the benefit of using risk-adjusting design, we use two different ap-
proaches to summarize the results: 1) intra-trial dose allocation. 2) probability of
correct dosing, under-dosing and over-dosing based on the final model estimate in the
end of the trial.
Intra-trial dose allocation: The model based sequential design repeatedly up-
dates the dose-toxicity model based on the available data to treat the next enrolled
patient on the current best estimate of the MTD. This characteristic suggests that
its advantage is not only to obtain more accurate dose recommendation in the end
of a trial, but also to maximize the chance of receiving correct dose for the patients
participating the trial. Risk-adjusting design directly incorporates individual drug
tolerability when assigning doses to patients enrolled in a trial, thus enhancing the
dosing accuracy for each individual patient, which is desirable feature from an ethical
perspective. We evaluate the intra-trial dose allocation of risk-adjusting design and
make comparison with conventional design under various scenarios using simulated
data.
We denote the assigned dose for the i’th patient with covariate z following the risk-
adjusting design as x̂i(z), and the dose which should have been received according to
the simulated true tolerability, xi(z). Tables 5.5, 5.6, and 5.7 list the cross tabulations
of xi and x̂i divided by the number of simulated trials two thousand, under specific
scenarios defined by risk effect size, toxicity profile, and p threshold. The number
listed in the i’th row and j’th column in each square represents the percentage of
patients who should have received dose i while actually received dose j, j, i = 1, . . . , K.
The sum of the each K ×K square equal to 100.
Since the patient-specific risk factor z is simulated using a normal distribution
that samples more patients with covariate values around the mean z0, a majority of
patients is expected to receive the lowest dose under the most toxic scenario (scenario
1), and the highest dose under the least toxic scenario (scenario 5). Therefore, the
highest row percentage in each square shifts from dose 1 to dose 5, and within that
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row most patients are assigned on the correct dose (j = i) or neighboring doses.
Each square can be further summarized using the proportion of correct dosing,
under dosing and over dosing, which are the total proportions fall on, below and
above the diagonal line. These summaries are listed in Table 5.8. When there is a
strong risk effect (γ = −4 or γ = −2), the conventional design without adjusting
for risk factor (p threshold equals to 0) is least desirable, as it yields the lowest
correct dosing proportion. The dosing accuracy increases as the p threshold increases
to 0.20, and levels off as p continues to increase. Meanwhile, using risk-adjusting
design by relaxing p value threshold effectively reducing both over dosing and under
dosing proportions. Specifically, compared to the conventional design (p=0), using
risk-adjusting design with p threshold 0.20 increases the correct dosing proportion
from 33.2% to 42.1% (a relative increase of 27%) for γ = −4, and increases from
43.4% to 46.3% (a relative increase of 6.7%) for γ = −2. However, when there
is no risk effect (γ = 0), the conventional design (p=0) remains the most suitable
design and yields the highest correct dosing proportion and lowest under/over dosing
proportions. However, even in the least favorable scenarios for using risk-adjusting
design(γ = 0), the risk-adjusting design seems fairly robust and does not lose much
dosing accuracy, compared to the conventional design, as the difference in correct
dosing proportion using these two designs (p=0 vs. p=0.20) is only 2%.




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CHAPTER 5. CRM WITH CONTINUOUS RISK FACTOR 85
Dosing accuracy based on the final model estimate: As an end product of
the phase I dose finding trial, the dosing algorithm and its accuracy in predicting the
dose assignment of a future patient is of most interest. In the end of a risk-adjusting
design, the K + 1-parameter model will be fitted on all patients enrolled in the entire
trial to obtain the final model estimate α̂k and γ̂. Covariate-toxicity curves can be
constructed using these estimates and used to guide the dose assignment for future
patients. A map can also be generated between covariate value and the corresponding
risk-adjusted MTD using the same dosing algorithm described in the earlier sections.
On the x-axis of this map, covariate z is divided into consecutive intervals, with
each interval corresponding to an assigned dose level. There are up to K consecutive
intervals: and their corresponding MTDs are 1, . . . , K respectively. Similar map and
covariate intervals can be obtained based on the γ and αk’s values specified in the
true scenarios (right hand side graphs in Figures 5.4, 5.5, and 5.6: Oftentimes these
two sets of intervals do not align with each other perfectly. An extreme case would
be the design regards all patients exchangeable and recommends a common MTD in
the end, whereas these patients should have received different MTD’s according to
their individual risk levels, or vice versa. We further compare the dosing intervals at
the end of each simulated trial with the dosing intervals under the true scenarios, and
define the correct, over and under dosing intervals to be the covariate regions where
the estimated risk-adjusted MTD is the same as, above or below the true MTD. We
use C,O, and U to represent the union of the intervals on the real line that falls in
one of the three categories. C = {z : x̂(z) = x(z)} = ∪Kk=1{z : x̂(z) = x(z) = k},
O = {z : x̂(z) > x(z)}, and U = {z : x̂(z) < x(z)}. x̂(z) indicates the estimated
MTD at covariate z based on the model and x(z) indicates the true MTD at covariate
z based on the true scenario. The probabilities of correct dosing, under dosing and
over dosing can be calculated as the total sampling probabilities over each of these
three sets of intervals on the real line.
Since we use normal distribution with mean z0 = 3.45 and standard deviation
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We further average the probabilities over K toxicity scenarios to obtain an average
performance in terms of correct dosing, over dosing and under dosing for each true
γ value and design parameter p threshold. The average performance is listed at the
bottom of the table 5.9. Note that the sum of the three probabilities is 1. The three
summary probabilities are plotted against the p value threshold in Figure 5.7. In
the top left graph, the correct dosing probabilities are plotted against the p value
threshold from 0 to 0.75, with each line representing a different true γ value. The
graphs for over dosing probabilities and under dosing probabilities are generated in a
similar manner. As demonstrated in the graph, when there is a very strong risk effect
(γ = −4), the correct dosing probability increases from 38.2% using the conventional
design (p=0) to 56.5% using the risk adjusting design with p value threshold 0.10,
representing a 48% relative increase in correct dosing. As the p value continues to
increase, the correct dosing accuracy plateaus and remains at a high level. The similar
gain in correct dosing probability is also observed when there is a relatively strong
risk effect (γ = −2), that the probability increases from 54% using conventional
design (p=0) to 59.8% using risk-adjusting design with p value 0.10, representing
a 11% relative increase. On the contrary, when there is no risk effect (γ = 0),
the conventional design is the most suitable design and yields the highest accuracy
with correct dosing probability 74%, and this probability tend to decline slowly as p
threshold increases as more trials would enter the risk-adjusting stage by chance.
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These graphs may be used to guide the choice of the design parameters if such
risk-adjusting design is of consideration. For example, to conduct a trial to identify
the individual MTD for patients treated with irinotecan, we probably can choose a
design with p threshold around 0.10 as it yields the highest correct dosing probability
under both true scenarios with strong risk effects. Meanwhile, even if the baseline
clearance level turns out not to relate with the toxicity outcome as much as expected,
using the risk-adjusting design suffers minor loss in dosing accuracy compared to the
conventional design as the probability of correct dosing only decreases from 74% to
71.7%, a roughly 2.3% decrease.
The rest of the graphs suggests that the risk-adjusting design not only increases
correct dosing probability, but also decreases both over dosing and under dosing
simultaneously, when there is true risk effect. Therefore the risk adjusting design
effectively increases the dosing accuracy by correctly allocating the patients to their
respective MTD according to their individual risk level.
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Figure 5.7: Correct, over and under dosing probabilities based on the final model estimate.
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Chapter 6
Conclusions and Discussions
This dissertation undertook tasks to address two different but related topics for
model based sequential design for dose-finding. First we developed a theoretical
framework to build a two-stage likelihood CRM. Such design addresses the ethical
concerns on the overly aggressive dose escalation at beginning of the trial of conven-
tional one-stage Bayesian CRM design by pre-specifying sufficient number of patients
are tested on lower dose levels. While it is desirable to escalate slowly to not over-
shoot the target dose level, overly conservative escalation will cause incoherent dose
escalation upon transition into the model based design, i.e., the first model based
dose assignment upon observing the first DLT will continue to escalate despite the
previous patient has already experienced a toxicity at a lower dose level. To guard
against such unethical dose escalation, we propose using the most conservative and
coherent design, and proved the unique existence of the most conservative and co-
herent initial design. In practice, however, we do not always have to use the most
conservative and coherent initial design. Rather, it can be used as a starting point
and further pruned according to sample size constraint.
In the second topic, building upon the likelihood CRM design, we proposed a
multi-stage design using a semi-parametric model to incorporate an external risk
factor and identify patient specific MTD. The design uses likelihood method which is
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computationally economical and easy to implement. The design allows the flexibility
of using conventional CRM to identify a common MTD for homogeneous patient
population when there is lack of risk effect, and switches into risk-adjusting design
when risk effect is sufficient. While developed for the situations with continuous
risk factor and discrete doses, the method can be easily generalized for categorical
risk factor and continuous dose. The method was illustrated and compared with the
conventional CRM design for homogeneous study population under various simulated
scenarios. In the future, more evaluations will be conducted to compare our design
to the existing methods for dose-finding studies with patient heterogeneity [21; 22;
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